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Postmenopausal women have higher risk of coronary 
artery disease and peripheral vascular disease. Hormone 
replacement therapy (HRT) effectively reduces the risk for 
coronary artery disease. It is believed that HRT can also 
reduce the risk for peripheral vascular disease. The aims of the 
thesis are to investigate whether the administration of oestrogen 
reduces the resistance to blood flow in the peripheral vascular 
system; to find out whether combined oestrogen and 
progestogen can also reduce the peripheral vascular resistance; 
as well as the relationship between peripheral vascular 
resistance and serum oestradiol concentration. Patients with 
surgical menopause were randomized into three groups: control, 
oestrogen only and combined oestrogen and progestogen. The 
pulsatility index (PI) of brachial, dorsal pedis, popliteal and 
radial arteries was measured at 0，2，4 , and 6 months after 
treatment. Serum oestradiol concentration was tested during 
each visit. The change of PI was analyzed by Wilcoxon 
1 
matched-paired s igned-ranks test . The rela t ionship between 
serum oestradiol and PI was analyzed by Mann-Whitney test. 
There were for ty-eight cases in the study. The pulsat i l i ty 
indices in all t reatment groups af ter 2 months were 
s ignif icant ly reduced but not in the control group. This ef fec t 
persis ted af ter 6 months of t reatment . Serum oestradiol and 
pulsat i l i ty indices were negat ively correlated. The results 
confirm that HRT is associated with a reduction in PI of 
peripheral vessels, ref lect ing a reduction in resistance of 
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I.A.1. Definition of the Menopause 
The menopause is the permanent cessation of 
menstruation, which occurs as a result of the failure of ovarian 
follicular activity (Report of a WHO Scientific Group, 1981). 
It is derived from the Greek words 'menos' and ‘ p a u s e � � w h i c h 
mean ‘month, and ‘to stop' respectively. Apart from its 
reference to naturally occurring ovarian failure, the menopause 
may also be used to describe amenorrhoea secondary to surgical 
removal of the ovaries, irradiation，or as a result of 
chemotherapy. 
In Caucasian women，the menopause occurs at around 51 
years of age, with a normal range from 40 to 55 years. The 
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t ime of onset appears to be independent of socioeconomic 
factors , race, weight and height, al though it tends to occur 
earlier in those who have serious malnutr i t ion or are cigarette 
smokers. The l i fe-expectancy of Caucasian females has been 
reported to average 82.8 years (Chris t iansen et al, 1996) which 
means that around one-third of a woman ' s l i fe is potent ial ly in 
a state of oestrogen-def ic iency. This state may be accompanied 
by prolonged symptomatic and metabolic complicat ions which 
can have a profound effec t on quality of l ife, general health and 
longevity. 
The climacteric is the phase in the aging process of 
women which marks the transit ion f rom the reproductive to the 
non-reproductive stage of l ife. This transit ion occurs around 
the time of the menopause when ovarian funct ion gradually 
becomes compromised. During this time symptoms result ing 
from oestrogen deficiency begin to appear. 
I.A.2. Pathophysiology of Ovarian Failure 
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Aging of the ovary commences before birth when there is 
a gradual decrease in the number of primordial foll icles 
(Sherman et al, 1976). At puberty, the percentage of growing 
foll icles increases markedly, and this number is approximately 
maintained during the reproductive stage and declines in the 
climacteric period. 
Nearly a decade before the menopause, there is a decrease 
in follicular hormone production and a resultant increase in 
hypothalamic pituitary activity due to the resistance of the 
remaining ovarian follicles (Chakravanti et al, 1979). There is 
a gradual increase in levels of follicle stimulating hormone 
(FSH) and luteinizing hormone (LH) and a reduction in the 
number of responsive theca interna and granulosa cells which 
are the sites of production of oestrogen and progesterone. 
During the climacteric, the levels of androgens, particularly 
those associated with ovarian secretion，also decline, but the 
decline is proportionally less than that of the oestrogens 
(Longcope et al, 1985). Anovulation and luteal phase 
inadequacy become common as the menopause approaches. The 
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presence of inadequate proges te rone product ion in the presence 
of unopposed oes t rogen secret ion can cause dys func t iona l 
u ter ine b leeding and endometr ia l hyperplas ia if l e f t untreated. 
As t ime progresses there are no fo l l ic les remaining which 
can respond to pi tui tary s t imulat ion, and ovarian fa i lure is 
complete . Concent ra t ions of serum oestradiol decrease fur ther , 
and menst rua t ion ceases. However , the stroma remains active 
and there is an increase in interst i t ia l cell product ion of 
androgens (andros tenedione and tes tosterone) . This accounts 
for the emergence of androgenic fea tures af ter the menopause, 
such as greasy skin, acne, and fac ia l hair. There may also be 
adverse changes in the l ipid prof i le (explained below). The 
latter contr ibutes part ly to the increase in cardiovascular 
disease r isk which is found in postmenopausal women. 
Although the adrenals secrete only small amounts of 
oestrogen i tself , they produce substantial amounts of oestrogen 
precursors such as the androgen dehydroepiandrosterone and its 
sulfate (Longecope et al，1985). Although these are all weak 
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androgens， their pr imary impor tance is to act as precursors for 
convers ion to oest rogen in per iphera l t issues. 
LB. Effects of the Menopause 
Oestrogen def ic iency associa ted with the menopause can 
lead to a variety of acute, medium and chronic physical and 
psychological problems. 
I.B.1. Acute Effects 
Acute symptoms normal ly appear within weeks to months 
of the menopause, al though they may occur up to a decade 
earl ier (Bungay et. al, 1980). The acute symptoms include hot 
flushes and sweating. Hot f lushes are an uncomfortable feel ing 
of heat, usual ly beginning in the upper chest and spreading to 
the neck and face . The duration is usually 30 seconds to 
several minutes. In addit ion to the above, headaches, loss of 
energy, depression, insomnia, irri tabili ty, anxiety and a loss of 
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conf idence may also occur (McKinlay et. a l，1974). These 
episodes can disrupt a w o m a n ' s sense of well being and can 
cause p rob lems in her social and profess iona l l i fe . It has been 
repor ted that at least 82% of pos tmenopausa l Caucas ian women 
suf fe r f r om acute symptoms for at least one year a f te r the 
menopause and 25% of these symptoms persis t for more than 5 
years (McKinlay et. al, 1974). Another study repor ted that 
70% of Caucas ian females exper ienced vasomotor symptoms for 
2 years or more a f te r the menopause (Samsioe et. al, 1985). 
There appears to be some racial d i f fe rence in the repor t ing of 
hot flushes and sweating, wi th postmenopausal Chinese women 
exper iencing fewer of these symptoms than Caucasians (Haines 
et al，1994). 
I.B.2. Medium Term Effects 
Medium term complaints usually occur several months to 
years af ter the menopause. It takes this long for oestrogen 
def ic iency to a f fec t the genitourinary tract, and atrophic 
changes can contribute to urinary urgency, nocturia and 
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incont inence. In addit ion, there may be impaired sexual 
funct ion with poor arousal and lubricat ion, a loss of sensat ion 
and less f requent orgasm. There may also be a thinning of 
collagen in the skin and a reduced amount of collagen in 
support ing l igaments which may cause jo in t s t i f fness (Oriloa et 
al, 1989). 
LB.3. Chronic Effects 
Chronic e f fec t s of the menopause usually take some 10-15 
years to become apparent. The two most widely reported long 
term ef fec ts of oestrogen def ic iency are osteoporosis and an 
increased risk of cardiovascular disease f rom atherosclerosis. 
I.B.3.a. Osteoporosis 
Osteoporosis results f rom a disturbance in the balance 
between bone resorption and formation. Whilst there is an 
increase in bone loss in both males and females with advancing 
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age，oes trogen loss associa ted with the menopause accelera tes 
this p rocess in women (Mel ton et al, 1990). Pos tmenopausa l 
bone loss is most marked in the distal radius, the neck of the 
femur and in the ver tebral bodies (Stevenson et al, 1990). 
Oest rogen def ic iency over a per iod of 10-15 years may cause a 
woman to lose one-third to one-half of her you th fu l bone mass 
(Ett inger et al, 1988). Forty percent of Caucasian women will 
face os teoporos is- re la ted f rac tu res by the age of 70 while 15% 
will su f fe r a hip f rac ture by 80 years of age (Bilezikian & 
Silverberg, 1992). In Hong Kong the incidence of osteoporot ic 
hip f rac ture has increased 2- fo ld in those aged 70 years or more 
over the past three decades. Damage to the vertebral bodies 
may lead to a so-called Dowager ' s hump f rom severe kyphosis 
and poss ibly respiratory and cardiovascular embarrassment . 
Hip f rac ture resul ts in great pain and disabil i ty and has a high 
associated morbidi ty and mortal i ty. Although the rate of bone 
loss is highest in the f i rs t f ew years af ter the menopause, it 
continues until death. Increased longevity calls for a greater 
emphasis on the prevention of bone loss. 
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LB.3.b. Coronary Artery Disease (CAD) 
Apart f rom osteoporosis , it has now become recognized 
that the menopause is also a risk fac tor for cardiovascular 
disease (Oliver et al, 1959; Szna jderman et al, 1963; Gordon et 
al, 1978). Whils t the incidence of coronary artery disease 
(angina pector is , myocardia l infarc t ion, acute cardiac death) is 
higher in men than in women of all ages, the gender d i f fe rence 
nar rows af te r the menopause (Kalin et al, 1990)，so that by the 
age of 70 there is l i t t le d i f fe rence between the two sexes. In 
Hong Kong the sex rat io (male : female) for CAD in the age 
group of 30-49 years is 5:1. However, this rat io fa l ls to 2:1 in 
those aged above 65 years (Public Health Report N o . l , 1994). 
Although the number of CAD deaths has decreased in the 
United States and in other developed countr ies over the past 
two decades, the number of deaths at tr ibutable to 
cardiovascular diseases is increasing in Hong Kong as well as 
other Asian countr ies (Hughes et al，1986; Wu et al，1983). In 
Hong Kong, the total number of CAD deaths per 100,000 
populat ion nearly doubled f rom 28.4 in 1972 to 54.7 in 1992. 
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In add i t ion，CAD is the second leading cause of death in 
women in Hong Kong (Publ ic Heal th Repor t No. 1，1994). As 
in other countr ies , the inc idence of CAD in Hong Kong is also 
higher in pos tmenopausa l than in p remenopausa l women. 
The adminis t ra t ion of hormone rep lacement therapy 
(HRT) appears to reduce the r isk of cardiovascular disease in 
pos tmenopausa l women (Gordon et al, 1978; Oliver et al, 1959; 
Szna jderman et aI, 1963), but the mechanisms by which this 
pro tec t ion is provided are still incomplete ly unders tood. Less 
than one third of the cardioprotect ive e f fec t of es t rogen is 
thought to be due to benef ic ia l changes in c i rculat ing l ipids and 
l ipoprote ins (Orimo et al，1993)，A direct act ion of oestrogen 
on blood vessels has been considered as another important 
mechanism. It has been suggested that oestrogen produces 
\ 
vasodi la ta t ion and improves blood f low. This thesis will 
examine the e f fec t of HRT on peripheral blood f low in 
postmenopausal women. 
18 
Detai ls of r isk fac tors for coronary artery disease, the 
associat ion between the menopause and CAD risk, the impact of 
HRT on CAD risk and a descr ipt ion of previous studies on the 
e f fec t of HRT and blood f low will be provided in the l i terature 
review. 
I.C. Management of the Menopause 
The idea to approach the menopause as a pathological 
rather than a physiological process became popular in the 
1960s. The prescript ion of HRT for postmenopausal women 
has gained increasing populari ty, especially over the past 20 
years. 
Large double blind, placebo-controlled crossover studies 
have demonstrated significant improvement in a variety of 
psychological and physical symptoms after treatment with HRT 
(Campbell et al, 1977). The range of symptoms for which 
oestrogen has been described as being effective is extremely 
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broad but vasomotor symptoms respond best to th is t rea tment 
(Hunt et al，1988). HRT has been proven to be success fu l in 
the t rea tment of these p rob lems in 90 per cent of Caucasian 
women (Hunt et al, 1988). Depress ion, insomnia，palpitat ions, 
formication，breast pain and loss of abil i ty to concentra te may 
also respond to oestrogen t reatment . Voiding d i f f icu l t ies , 
ur inary f requency and urgency also improve with oestrogen 
adminis t ra t ion (Coope et al, 1975; Denners te in et al，1979; 
Versi et al, 1988). 
Oestrogen also prevents bone loss (Chris t iansen et al, 
1981) and reduces the incidence of osteoporot ic f rac tures in 
postmenopausal women (Gordan et al，1973). This potent ial ly 
lowers the mortal i ty rate f rom osteoporot ic hip f rac tures 
(Pagainini-Hil l et al，1981; Ross et al，1989). In addition, 
oestrogen t reatment also has a benef ic ia l e f fec t on both 
cardiovascular mortal i ty (Vessey et a l，1988) and on the 
severity of coronary occlusion in women with angiographical ly 
confi rmed ischaemic heart disease (Gruchow et al, 1988). 
There is now a consensus that HRT is protective against 
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cardiovascular disease and may provide up to a 50 per cent 
reduct ion in l ikely mortal i ty in postmenopausal users of this 
t reatment (Ross, 1981; Hunt et al, 1987). This will be 
described in more detail in the l i terature review. 
I.C.1. Hormone Replacement Therapy 
Hormone replacement therapy implies the administrat ion 
of low dose oestrogen replacement with or without a 
progestogen. 
Oestrogen may be administered orally in tablet form, 
through the skin as a percutaneous gel or t ransdermal patch or 
else as a subcutaneous implant. It may also be administered 
vaginally, but this route is usually reserved for the treatment of 
local symptoms. Unopposed oestrogen predisposes to the 
development of endometrial hyperplasia and carcinoma, and 
those postmenopausal women who have not had a hysterectomy 
should receive a progestogen in addition to oestrogen to prevent 
these complications. Oestrogen may be prescribed cyclically or 
on a continuous basis. Progestogens are commonly given 
21 
cycl ica l ly , in which case they usual ly induce regular 
wi thdrawal b leeding . Those women who have been menopausa l 
fo r a per iod of yea r s may be given a proges togen cont inuously , 
and wi th th i s reg imen there is usual ly no associa ted b leeding as 
the endomet r ium remains a t rophic . The pharmacodynamic 
proper t ies of exogenous oes t rogens vary with d i f f e ren t routes， 
t rea tment reg imens and components of adminis t ra t ion . 
LC.2. Oestrogens 
Oestrogen replacement therapy is appropr ia te t reatment 
for all c l imacter ic problems caused by ovarian fa i lure . The 
pharmacodynamic proper t ies of exogenous oest rogens vary with 
the route of adminis t ra t ion. 
I.C.2.a. Oral Oestrogens 
Oral oestrogens are the most commonly used method of 
administrat ion and are a convenient form of t reatment. 
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Oestrogen adminis tered in this form enters into the 
enterohepat ic c i rculat ion and the ‘ f i r s t - p a s s � e f f e c t enables the 
liver to convert one-third of the oestrogen to oestrone-3-
glucoronide which is excreted in the urine and bile without 
achieving its desired e f fec ts . Thus a rat io of oestrone to 
oestradiol of 2:1 is achieved with oral therapy whether oestrone 
or oestradiol is ingested, instead of the physiological rat io of 
1:2 that is present during the reproduct ive years . Oestradiol is 
the most e f fec t ive oestrogen but the hepatic metabol ism 
explains why oral oestrogens need to be given at higher doses 
than parenteral oestrogens in order to achieve the same 
symptomatic rel ief . Oral oestrogens cause an increase in sex 
hormone-binding globulin, cort isol-binding globulin and renin 
substrate and have a depressant e f fec t on anti thrombin III 
levels. Thus oral oestrogens may theoret ical ly be contra-
indicated in women with a history of clotting disorders or 
hypertensive disease. This ef fec t is much more pronounced 
with synthetic oestrogens which have a greater aff in i ty for 
oestrogen receptors and a greater resistance to enzymatic 
conversion. The contemporary view is that synthetic 
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oest rogens (ethinyl oestradiol and mest ranol) should not be 
used fo r HRT al though a comparison of bioequivalent doses of 
synthet ic and ‘ n a t u r a l � o e s t r o g e n has not been per formed. 
I.C.3. Progestogens 
Progestogens alone are indicated only in women who 
cannot receive oestrogen therapy. They are less ef fec t ive than 
oestrogen in suppressing hot flushes but have been shown in 
some studies to provide protect ion against bone loss (Lindsay et 
al, 1976). It is claimed that progestogens have a place in the 
t reatment of menopausal pat ients with a his tory of breast 
cancer. In usual practice, however, progestogens are not given 
alone to postmenopausal women. 
I.C.3.a. Combined Oestrogen and Progestogen Therapy 
The use of cyclical progestogens to ef fect a regular 
medical curettage and prevent endometrial pathology was first 
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descr ibed 50 years ago. Endometr ia l oes t rogen receptors 
pro l i fe ra te in response to unopposed oestrogen， leading to an 
increase in mitot ic act ivi ty and, in some users， overt 
mal ignancy (Gambrel l et al, 1982). Unfor tuna te ly , the 
recogni t ion that unopposed oestrogen had an adverse e f fec t on 
the endometr ium went unheeded for some time and it needed an 
American epidemic of endometr ia l cancer f rom the use of 
unopposed oes t rogens for combinat ion oest rogen/progestogen 
therapy to be accepted. Sturdee et al (1978) f i rs t showed that 
whils t t rea tment with oest rogens alone resul ted in a 15% 
incidence of endometr ial hyperplas ia , this was reduced by the 
addit ion of a cycl ical progestogen: a 7-day course resul ted in a 
4% incidence of hyperplas ia , whilst a 10-day course gave an 
incidence of 2%. With more than 12 days of progestogen 
t reatment per month there were no cases of hyperplasia . 
Concurrent progesterone therapy reduces the risk of 
endometr ial cancer by reducing oestrogen-receptor activity 
(Whitehead et al, 1986). Currently a 10 or 12 day course of 
progestogen is used in most oestrogen/progestogen packs and 
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recent s tudies have shown that the excess r isk of endometr ia l 
cancer has been e l iminated when this combinat ion is used. 
In women who wish to avoid cycl ical wi thdrawal bleeding 
it is poss ible to use a regimen of cont inuous oral oest rogen with 
a low dose of progestogen. Amenorrhea can usual ly be 
achieved within 6-9 months of the commencement of therapy 
al though t roublesome spott ing occurs in about 30% of pat ients 
before amenorrhea is induced. 
When adminis ter ing progestogens, both durat ion of 
t reatment and dose are important for endometr ial protect ion. 
Progestogens should therefore be included in a programme of 
HRT for all women who retain their uterus. However, 
proges togens are not without side e f fec ts and up to 30% of 
women will develop symptoms including headaches, depression, 
loss of energy，libido and bloatedness. 
I.C.4. Complications and Contraindications to Hormone 
Replacement Therapy 
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When one reviews why many postmenopausal women and 
their physic ians fai l to take or even prescr ibe oestrogen 
replacement , the answer is usual ly react ivat ion of uterine 
bleeding or, more commonly, the fear of cancer. 
The administrat ion of hormone replacement therapy has 
several disadvantages: 
1. The patient has to take regular medicat ion on a 
long-term basis. This is inconvenient and over a 
long period, a fai lure of compliance becomes more 
likely. 
2. Irregular bleeding may occur on patients taking 
combined HRT. 
3. Both oestrogenic and progestogenic side effects 
may occur. 
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A summary of the side e f fec t s of t reatment is shown in 
Table I.1. Other fac tors to be considered include the cost and 
inconvenience of taking the treatment . 
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Table I.1. Side effects of oestrogens and progestogens 
(McKeon et al，1994) 
m^»lill肩•w：lfwvl¾iWM¾,^^w¾mJ^^J^fn^y^"<^T^•rag^e8^LaMaJ^J^ w^•_F«•.f•f^l»^ww»>»>^.•»^«•_g^»•^••_^_•_M^•«_«»Ml•_«_p••ur«^•»rw»•_•^ •»^l•wr^幫_¾»_，M_yln^•',••^"•"^<^•.«^•^"_•>~»^•^•^*»~^"_^••>^鉀^•»-•»•層�•»>"u•^wJ|..-. ,-_^„ u_ 
Oestrogens Progestogens 
Nausea and vomiting Acne 
Breast tenderness and enlargement Breast tenderness 
Increased cervical mucus secretion Abdominal 
bloating 
Breakthrough bleeding 
Changes in libido 
Oedema or bloating, with possible 
worsening of conditions such as Lethargy 
asthma, epilepsy, and migraine due to 
fluid retention Insomnia 
Weight gain Loss of scalp hair 
Difficulty wearing contact lens Hirsutism 





Enlargement of uterine leiomyomata syndrome-like 
symptoms 
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Absolu te cont ra ind ica t ions to the adminis t ra t ion of HRT 
are cons idered to be breas t cancer , endometr ia l cancer , acute 
l iver disease，acute th rombophleb i t i s and undiagnosed vaginal 
b leeding (Mil ler et al, 1992). Relat ive cont ra indica t ions 
include a recent past h is tory of breast cancer, hyper tens ion, 
var icose veins, previous oest rogen related thrombot ic episodes, 
diabetes，endometriosis and f ibroids . However the support ing 
evidence regarding relat ive contra indica t ions is not strong, and 
natural oes t rogens have not been shown to cause an elevation in 
blood pressure in normotensive or hyper tensive women. Nor do 
they appear to alter coagulat ion, f ibr inolysis , platelet 
behaviour , or to increase the risk of deep vein thrombosis . 
There has been much confus ion regarding the inf luence of 
exogenous oestrogens on cardiovascular disease risk because of 
inappropriate extrapolat ion of oral contraceptive data. The 
contracept ives contain relat ively large doses of synthetic 
oestrogen that cause more side ef fec ts than the natural 
oestrogens used for HRT. 
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Endometriosis and fibroids are responsive to endogenous 
and exogenous oes t rogens and it is poss ib le that HRT may 
s t imulate the act ivi ty of these benign gynaecological 
condi t ions . In pract ice , th is does not present a cl inical problem 
as t rea tment can easi ly be discontii^ued and the doses used in 
HRT do not usual ly encourage the growth of f ib ro ids or 
promote endometr ios is . 
There is no evidence to implicate HRT in the aet iology of 
carcinoma of the cervix, nor is there any s ignif icant increase in 
the incidence of epithelial ovarian tumors fo l lowing oestrogen 
replacement therapy (Whitehead et al，1987). It seems likely 
that combined cyclical opposed hormone replacement therapy 
may confer some protect ive e f fec t against ovarian cancer in the 
same way as the oral contraceptive pill . 
The available epidemiological evidence relat ing to breast 
cancer is confus ing but most ly reassuring. The studies are 
mostly related to the use of oral conjugated equine oestrogens. 
Most studies have shown no signif icant change in breast cancer 
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r isk but there have been recent s tudies which show a slight 
increase in the re la t ive r isk of breast cancer a f te r 5 or 10 years 
of oes t rogen therapy (Brinton et al，1986). However , it may be 
that the sl ight excess is due to increased survei l lance, i .e. , 
breast examinat ion and mammography, and that women 
receiving oestrogen therapy have been compared with women 
who are not under their phys i c i an ' s care for such therapy. This 
• 
would lead to an increased diagnosis of ear ly-s tage tumors. It 
is not known whether the r isk is greater in high-r isk women 
with a fami ly his tory of breast mal ignancy or with benign 
breast disease. Such women should not be denied t reatment but 
should be of fe red oestrogen therapy with advice on regular 
se l f -examinat ion, physic ian examinat ion and a mammography. 
Breast cancer might still be a serious problem with either 
oestrogen or combined preparat ions. For a 50 year old women 
the basel ine l i fe t ime risk of CAD is around 45% and for breast 
cancer the risk is around 8%. However even if the benef i t of 
HRT with respect to cardiovascular disease appears to outweigh 
the risk of breast cancer, the user may be more concerned with 
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the slight increase in risk of breast cancer, and may choose not 
to use hormone replacement therapy. 
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CHAPTER 11 
LITERA TURE REVIEW 
This chapter will summarize the background information 
which resulted in the formation of the research hypothesis 
presented in this thesis. It will review the pathophysiology of 
atherosclerosis with emphasis on endothelial dysfunction, an 
important early event of the atherosclerotic process. The effect 
of the menopause on CAD risk factors and the epidemiology of 
CAD after the menopause will also be reviewed, as will the 
effect of HRT on the risk of CAD. On top of that, the effect of 
menopause on peripheral vascular disease will be reviewed. 
Then, the indirect and the direct effects of ' HR T on the 
cardiovascular system will be summarized. The final section 




Atherosclerosis is characterized by thickening and loss of 
elasticity of arterial walls. It represents a combination of 
changes in the intima of the arterial wall that favour the focal 
accumulation of lipids, complex carbohydrates and some 
constituents of blood. It is crucial in the pathogenesis of 
coronary artery disease, cerebrovascular insufficiency and 
peripheral vascular disease. Atherosclerosis develops as a 
reaction to chronic endothelial cell injury and may be 
exacerbated by hyperlipidaemia, hypertension, cigarette 
smoking and diabetes. The endothelial injuries most important 
in atherosclerosis ~nduce dysfunctional metabolic and structural 
changes which are accompanied by increased permeability to 
plasma constituents, including lipids, as well as adherence of 
monocytes and platelets to the endothelium (Blankenhorn and 
Hodis, 1993). Endothelial dysfunction is lack of control of 
smooth muscle and manifests itself as the inability to maintain 
adequate blood flow. These processes may be increased by the 
synthesis of vasoactive agents and by smooth muscle migration 
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from the media into the subintima with later proliferation. 
Moreover, a fibrous cap develops as a barrier between the 
bloodstream and the lipid pool. As these lesions increase In 
size, the plaques slowly occlude the artery and predispose to 
thrombosis and narrowing of the vessel wall which causes 
ischaemia. Eventually, this may lead to the clinical picture of 
myocardial infarction and sudden death. 
As mentioned above, the endothelium has a critical role 
In the control of blood flow and the interaction between the 
blood and the vessel wall. It is not only an important in the 
establishment of atherosclerosis (Ludmer et aI, 1986; de Zeiher 
et aI, 1991) but also in the appearance of complications, such 
as thrombosis and vasospasm (Vane et aI, 1990; Dzau et aI, 
1993) which may be fatal. Age-related arterial endothelial 
dependent dilatation declines around the time of menopause, 
and this is consistent with a suggested protective effect of 
oestrogen on the vessel wall (Celermajer et ai, 1994). 
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II.B. Risk Factors for Coronary Artery Disease 
The aetiology of coronary artery disease is a complex and 
multifactorial process in which a number of risk factors may act 
in combination. The greater the number and severity of risk 
factors, the greater the likelihood of disease and death. The risk 
factors for coronary artery disease include: women 55 years of 
age or above, premature menopause without oestrogen 
replacement therapy, males > 45 years of age, a family history 
of premature heart disease (death of a parent or sibling before 
age 55), a history of peripheral or cerebrovascular disease, 
smoking, hypertension, HDL cholesterol < 0.9 mmol/L, LDL-C 
>4.1 mmol/L and diabetes (National Cholesterol Education 
Program 1993). An alternative classification of cardiovascular 
risk factors is as follows: 
Non-modifiable: age, sex, age at menopause, family history 
Potentially modifiable: serum lipids, blood pressure, cigarette 
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II.B.1. Age and Sex 
smoking, exerCIse, sex hormones, 
diabetes mellitus. 
With advancing age, atherosclerosis develops 
progressively in both sexes, although men are more commonly 
affected than women. Neither of these risk factors are 
modifiable. 
II.D.2. Age at Menopause 
This risk factor will be discussed later. 
II.D.3. Family History 
Coronary artery disease is often found in members of the 
same family (Greenlund et aI, 1997; Myers et aI, 1990). The 
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cause may be genetic factors or the ef fec ts of a shared 
environment in the same family (e.g. similar habits and diets). 
n.B.4. Serum Lipids 
The risk of CAD is posit ively related to raised serum total 
cholesterol (TC), low density l ipoprotein cholesterol (LDL-C) 
and tr iglyceride (TG) concentrations and inversely related to 
high density lipoprotein cholesterol (HDL-C) concentrations. 
Other lipid f ract ions including apoprotein A-I, apoprotein B， 
HDL2-C and HDL3-C and also lipoprotein(a) [Lp(a)] have also 
been identif ied as risk factors for CAD (Woo et al, 1993). 
n.B.5. Blood Pressure 
The risk of CAD is related to both systolic and diastolic 
hypertension. Hypertension may damage the intima and 
accelerate the precipitation of atherogenic materials. Increased 
intravascular pressure may also induce cholesterol penetration 
39 
into the int ima cel ls with increased wall damage (Kannel et al, 
1972). 
II.B.6. Smoking 
Cigaret te smoking is an important modif iable risk factor 
for CAD and the risk is associated with the length of t ime the 
individual has smoked and the number of cigarettes each day. 
II.B.7. Diabetes Mellitus 
Diabetes mell i tus or impaired glucose tolerance is 
associated with an increased risk of CAD. The magnitude of 
risk can be altered by good diabetic control. 
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II.C. The effect of the Menopause on Risk Factors 
for Coronary Heart Disease 
Before the menopause , coronary ar tery disease is 
uncommon in women who do not smoke and have no other 
predispos ing fac tors such as hyper tens ion, hyper l ip idaemia or 
diabetes . Women have similar risk fac tors for a therosclerot ic 
disease as men except that women have an addi t ional fac tor 
which is the menopause . Coronary artery disease is f ive t imes 
more common in men than in premenopausal women, but 
fo l lowing the menopause the risk of heart disease in women 
approaches that of men (Studd et al, 1988). In addit ion 
cardiovascular disease risk is greatly accelerated in those 
women who undergo a premature menopause, and this 
correlates with the durat ion of ovarian fai lure (Johansson et al, 
1975; Gordon et al，1978). 
II.C.1. The Effect of the Menopause on Lipids and 
Lipoproteins 
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Prior to the menopause , serum LDL-C concen t ra t ions are 
lower in women than in men, and serum HDL-C levels are 
higher , but a f t e r the menopause LDL-C concent ra t ions in 
women r ise and those of HDL-C tend to decrease (Nat ional 
Center fo r Heal th Stat is t ics , 1964 and 1967). Raised 
concent ra t ions of TC and LDL-C and low concent ra t ions of 
HDL-C are independent r isk fac tors for CAD in both men and 
women. (Heiss et al，1980; Kannel et al，1976). Concent ra t ions 
of TG also increase af ter the menopause , and there is evidence 
to suggest that TG are a more important risk fac tor in women 
than in men. The rat io of p lasma to ta l /HDL choles terol has 
been suggested to be the most power fu l predic tor of premature 
development of CAD (Castel l i et al, 1984). There is a 
substant ia l increase in this rat io in pos t -menopausal women, as 
observed prospect ively in the Framingham Study (Kannelet al, 
1987). This could help to explain the increased susceptibi l i ty 
of pos t -menopausal women to CAD. Concentra t ions of other 
l ipids and l ipoproteins including apoprotein A and apoprotein 
B, HDL2-C and HDL3-C and Lp(a), also change af ter the 
42 
menopause in a direction which favours the development of 
atherosclerosis . 
However, hyperl ipidaemia only accounts for some of the 
increase in risk af ter the menopause. The increase in total 
cholesterol alone af ter the menopause will predict a rise of at 
least 38 per cent in the incidence of CAD. This is less than the 
actual increase in incidence, which is at least 100 per cent 
(Gordon et al, 1978). Some of the shortfall may be accounted 
for by the other changes which occur after the menopause. 
II.C.2. The Effect of the Menopause on Glucose and 
Insulin Metabolism 
Disturbances of glucose and insulin metabolism are also 
of major importance in the development of CAD. Fasting 
plasma insulin has been shown to be a strong predictor of 
coronary heart disease in several prospective studies (Pyorala 
et al, 1979，Welborn et al, 1979). It has been suggested that 
women are less prone to heart disease than men because they 
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have more ef f ic ient insulin-mediated glucose homeostasis by 
virtue of greater insulin sensitivity (Donahue et al, 1987， 
Orchard et al，1982). However high fast ing plasma insulin in 
post-menopausal women suggests that the increase in CAD after 
the menopause might be due in part to reduced insulin 
sensitivity. The insulin resistance which occurs in 
postmenopausal women is due to a reduction in pancreatic 
insulin secretion and reduced insulin elimination rates (Walton, 
et al, 1993). It is well recognized that diabetic women have a 
higher incidence of CAD than diabetic men and this suggests 
that the sex hormone influences on glucose and insulin 
metabolism may be of particular significance with regard to 
CAD risk. 
II.C.3. The Effect of the Menopause on Coagulation 
Changes in the clotting profile have also been observed in 
association with menopausal status, including an increase in 
fibrinogen and factor VII (Meade et al, 1990), antifibrinolytic 
factor and plasminogen activator inhibitor-1 (Heinrich et al, 
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1991). Concentrat ion o f L p ( a ) also increase and these may also 
increase CAD risk. 
II.C.4. The Effect of the Menopause on the Arterial Wall 
Oestrogen def ic iency also has a direct e f fec t on the 
arterial wall result ing in a change in arterial blood flow. 
Proteins associated with the oestrogen receptor are found in 
arterial walls throughout the human arterial tree (Padwick et al, 
1989)，and it is thought that oestrogen deficiency may reduce 
arterial compliance and decrease blood flow. This will be 
described in detail later. 
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II.D. The Risk of Coronary Artery Disease After 
theMenopause 
In Chinese populat ions ( including Hong Kong, China and 
Taiwan), the prevalence of CAD, the incidence of mortal i ty 
f rom CAD, and the incidence and death rates of acute 
myocardial infarct ion have been about 2/3 of Caucasians. In 
the United States some 42.5% of deaths among women over the 
age of 50 years are due to cardiovascular disease. In Australia 
similar f igures apply, with over 40% of deaths among women 
being at tr ibutable to cardiovascular accidents. The rate of 
death f rom myocardial infarct ion among women almost exactly 
mirrors that in men but occurs 10 years later (Wren et al, 
1985). Protect ion is thought to be mediated by the endogenous 
oestrogen which women produced until the age of the 
menopause. Although the incidence is decreasing in the West, 
it appears to be increasing in these Chinese populat ions (Woo 
et al, 1989). In Hong Kong, heart disease accounts for 15.6% 
of all deaths, second only to cancer (Public Health Report 
N o . l , 1994). As in most other races, the incidence of CAD is 
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higher in pos tmenopausa l than in premenopausa l Chinese 
women. 
II.D.1. The Effect of the Menopause on Peripheral 
Vascular Disease (PVD) 
The menopause is not only associated with an increased 
risk of CAD, but also with an increased risk of per ipheral 
vascular disease. The incidence of PVD also increases with 
age, smoking and low levels of h igh-densi ty l ipoprotein 
(Newman et al，1991). 
Coronary artery disease is the primary cause of death in 
per ipheral arterial occlusive cases. Peripheral vascular disease 
may be asymptomatic or resul t in intermit tent claudication. 
Hospi ta l izat ion for peripheral arterial occlusive disease is 
usually due to severe occlusive disease which causes 
thrombotic occlusion, ischaemic skin ulceration, or gangrene. 
In the United States, peripheral arterial occlusive disease 
is an important cause of morbidi ty and health care expenditure 
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among older people . From 1985 to 1987，an es t imated 229 ,000 
men and 184,000 women per year were d ischarged f rom 
hospi ta l s wi th a d iagnos is of chronic per iphera l ar ter ial 
occlus ive disease . Ar te r iography is pe r fo rmed during 
approximate ly 88,000 hosp i ta l iza t ions per year and aor toi l iac 
femora l bypass dur ing 31 ,000 hospi ta l iza t ions per year . The 
discharge d iagnosis of acute per iphera l ar ter ia l occlusive 
disease is made in approximate ly 60,000 men and 50,000 
women each year , and 28,000 embolec tomies or th rombectomies 
of lower l imb ar ter ies are per formed . However , a l though this is 
an impor tant cause of morbidi ty , f ew deaths are at t r ibutable 
direct ly to the disease (Gil lum et al, 1990). 
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II.E. The Effect of Hormone Replacement 
Therapy on Coronary Artery Disease Risk 
Large case-control and prospect ive cohort s tudies have 
shown that oes t rogen reduces the r isk of CAD and myocardia l 
in fa rc t ion in pos tmenopausa l women. Meta-analys is of relevant 
s tudies has shown a 45% decrease in the risk of cardiovascular 
disease in women who have received oestrogen replacement 
therapy (Sull ivan et al, 1988). 
More than 30 epidemiological studies have found that 
pos tmenopausal women who use oestrogen are at lower risk for 
coronary artery disease than those have not used oestrogen. 
Evidence f rom animal (Pick et al，1952a & b; Ludden et 
al，1942) and autopsy (Burch et al, 1974) studies indicates that 
exogenous oestrogens inhibit the development of 
atherosclerot ic coronary artery lesions. This is supported by 
coronary angiographic studies, where lower levels of coronary 
artery occlusion have been found in women treated with 
49 
exogenous oes t rogens than in untreated women (Gruchow et al, 
1988; Sul l ivan et al, 1988; McFar land et al, 1989). 
For all ep idemiologica l s tudies in humans combined, the 
relat ive r isk of myocardia l in farc t ion was 0.56, with only the 
data f rom hospi ta l -based case-control s tudies suggest ing a 
small non-s ign i f ican t increase in risk (r = 1.33). 
In hospi ta l case control s tudies (Table II.1), the relat ive 
risk var ied f rom 0.5 to 4 .3，with most s tudies showing no 
s ignif icant associat ion. However these studies had many 
l imitat ions, including recall bias and improper selection of 
controls . Therefore , the risk of CAD due to oestrogens may 
have been overest imated. 
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Table II.1. Hospital-based case-control studies of 
oestrogen use among patients hospitalized for myocardial 
infarction 
(MeKeon et al，1994) 
Studies Age Cases Oestrogen RR 
(Years) (Number) users (95%CI) 
im 
Rosenber 40-75 336 2.4 0 .71 
g et al, (0 .34-1 .46) 
1976 
Jick et al,^""""39-45 U 50 4 ^ 
1978a (0 .96-18 .84) 
J ick et al，""~35-45 U p7 ^ 
1978b (0 .07-3 .44) 
Rosenber 30-49 9 "Ti H ^ 
g et a l (current use). (0.71-2.74). 
1980， 24 1.88 
(past use) (1.09-3.24) 
Szklo et 35-64 39 28 ^ 
al，1984 
La ^ r ^ 5 TJs 
Vecchia et (current use). (0.68-5.01). 
al，1987 3 1.01 
_ J (past use) (0.31-3.27) 
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The popula t ion based case-control led studies are less 
biased (Table II.2.). The combined relative risk was 0.76 
(95%CI 0.61-0.94) . 
Table IL2. Population-based case-control studies of 
oestrogen use on heart disease 
(MeKeon et al, 1994) 
Studies Age Cases Oestrogen RR 
(years) (Number) use (95%CI) 
m 
Talbott et 39-64 64 5 0.34 
al, 1977 (0.09-1.30) 
Pfeffer et 5 0 - 9 8 “ 171 8.7 0.68 
al 1978 (current use) (0.32-1.42). 
‘ 30 0.86 
(ever users) (0.54-1.37) 
Ross et al, ^ f s l - ^ 
1981 (0.24-0.75) 
Bain et al, 3 0 - 5 5 “ 120 27 0.70 
1981 (current use) (0.50-1.10) 
53 0.65 
(ever users) (0.29-1.45) 
Adam et 50-59 76 3 ^ 
3j 1981 (current use) (0.41-2.28) 
, 12 0.65 
(cvcr users) (0.29-1.45) 
Beard et 40-59 86 27 0.55 
al，1989 (0.41-2.28) 
Thompson 45-69 ^ _ 1 1 2 
et al, (0.79-1.57) 
1989 
Rosenberg 4 5 - 6 9 ~ 858 - 0.90 
et al, (0.70-1.20) 
1993 
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P f e f f e r et al (1978) per formed a prospect ive case-control 
study to determine the associat ion between non-contracept ive 
oestrogen use and myocardial infarct ion. He selected 15,500 
postmenopausal women in a ret i rement vil lage in Southern 
Cal i fornia and used a f i rs t episode of myocardial infarct ion as 
his endpoint . It was found that the relative risk of having a 
myocardial infarct ion was 0.68 for current users and 0.86 for 
ever-users. 
Ross et al (1981) reviewed the associat ion between 
oestrogen replacement therapy and ischaemic heart disease, 
also in a ret irement community. He surveyed all women who 
died in the village between 1971 and 1975. When cases were 
compared with living controls, users of conjugated oestrogen 
had a relative risk of fatal coronary occlusion of 0.43. 
These data were supported by the retrospective case-
control study of Adam et al (1981). This revealed that nine of 
76 acute myocardial infarct ion cases (12%) had ever used 
hormonal replacement therapy compared with 26 of the 151 
53 
controls (17%). This is consis tent with an odds rat io for acute 
myocardia l infarc t ion in oestrogen ever-users of 0.65. 
Table II.3. summarizes f indings f rom four cross-sect ional 
studies on the degree of coronary disease and the use of 
oestrogens in women undergoing coronary arter iography. This 
study design avoided recall bias and solved the problem of 
control selection and response bias. 
Sullivan and colleagues (1988) conducted a 10-year 
retrospective case-control study to determine whether oestrogen 
replacement therapy inf luenced the prevalence of coronary 
atherosclerosis as measured by angiographic studies. Two 
thousand one hundred and eighty-eight postmenopausal women 
underwent coronary angiography between 1972 and 1984. 
There were 1444 women who had more than 70% stenosis in 
one or more of their main coronary arteries and 744 women 
who had no evidence of any occlusion. The odds ratio estimate 
of the risk of severe coronary artery disease in oestrogen users 
relative to the risk for non-users, after adjustment for age, 
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cigaret te smoking, diabetes, cholesterol and hypertension, was 
0.44. 
Gruchow et al (1988) also compared the degree of 
coronary artery occlusion between users and non-users of 
oestrogen. The odds rat io for the use of oestrogen in 
postmenopausal women indicated a stat ist ically signif icant 
protect ive e f fec t against coronary occlusion. 
McFarland et al (1989) conducted a retrospective review 
of coronary risk among 345 women who had undergone 
coronary angiographic studies. It was determined that 
oestrogen had a protective ef fec t of 0.5 for coronary occlusion 
for six months or longer of use. 
Sullivan et al (1990) published a second report on the 
relat ionship between postmenopausal oestrogen use, coronary 
stenosis and survival describing a study of another 2268 women 
undergoing coronary angiography. The survival in women with 
severe coronary occlusion was 97% for ever-users of oestrogen 
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therapy but only 60% for never-users . Among those women 
with mild to moderate occlusion, the survival of ever-users of 
oestrogen was 95.6% compared with 85% for never-users 
(p<0.03). Sullivan concluded that the maximum benef i t of 
oestrogen use was achieved by those women who had 
underlying atherogenic disease. 
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Table II.3. Cross-sectional angiographic studies of 
coronary artery occlusion among oestrogen users 
(MeKeon et al, 1994) 
Studies Age Case Oestrogen RR 
(Years) (Number) users (95%CI) 
1%} 
Sull ivan et Mean 2 ,188 4 .4% 0.44 
al，1988 62.8 (0 .29-0 .67) 
Gruchow 50-75 ^ 15.5% o 7 ^ 
et al, 1988 current users (0 .48-0 .73) 
Mcfar land~""35-59 2 ^ 4 l % 0^50 
et al, 1989 ever users (0 .30-0 .80) 
Sull ivan et ^ 2 ,268 10.5% 0 A 6 
al, 1990 ever users (0 .04-0.66) 
Hong et Mean 58 ^ 2jS% ^ 




A list of prospective studies is shown in Table II.4. 
Table II.4. Prospective studies demonstrating a 
cardioprotective effect of oestrogen 
(MeKeon et al, 1994) 
Studies Age Case Oestrogen RR 
(Years) (Number) users (95%CI) 
1 ^ 
Potocki et 60-70 158 52% 0.31 
al, 1971 (0.04-2.57) 
Hammond 46.3 6T9 49% 0.33 
et al, 1979 (0.19-0.56) 
Nachtigall 55 TeS 5 ^ 0.33 
e t a l , 1 9 7 9 (0.04-2.82) 
Bush et al, 40-69 2,270 8.5% 0.34 
1983 (0.12-0.81) 
Laffer ty et 45-60 U 4 4W0 0.17 
al，1985 (0.03-1.06) 
Stampfer et 30-55 32,317 ^ oTs 
al 1985 current (0.20-0.60) 
‘ 18% 0.7 
past users (0.40-1.20) 
57% 0.5 
ever users (0.30-0.80) 
Framingham"~50-84 1,234 TWo 1.94 
W i l s o n , current 
1985 14 1 7 6 
past users 
Framingham 50-59 ^ 15% ^ 
Eaker and (0.06-1.22) 
Castelli， 60-69 602 8% 168 
1987 (0.71-4.00) 
Bush et al, 40-69 2,270 2 ^ ^ 
1987 (0.16-0.88) 
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Pettiti et al, 18-54 ~ " 6 , 0 9 3 ~ 4 ^ 0.20-3.30 
1卯7 ever users 
Criqui et al, 50-79 1,868 39% 0 ^ 
1988 (0.45-1.24) 
Henderson 40-101 8,807 H% 0~80 
e t a l , 1 9 8 8 current (0.70-0.87) 
43% 0.62 
past users (0.43-0.90) 
Croft and 20-60 “ n e s t e d ~ 6.5% 0.80 
Hannaford， ever users 
198 9 
Avila, 1990 50-64 24,900 M % o7w 
current (0.40-1.30) 
Bush et al (1983) conducted an 8.5 year prospective study 
using a cohort of 2,70 postmenopausal women aged between 40 
and 69 years on the risk of cardiovascular disease. Among 
women with cardiovascular disease who were taking oestrogen, 
the mortality rate was 13.1/10,00 compared with 38.1/10,00 in 
non-users. The age-adjusted relative risk (RR) of death from 
cardiovascular disease in oestrogen users (n=593) compared 
with in non-users (n=1677) was 0.34 after adjusting for age, 
blood pressure, cigarette smoking, diabetes and cholesterol 
level. 
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Hammond et al (1979) per formed a retrospect ive review 
of 619 women who were oestrogen deficient . Af ter adjus tment 
for race, age and duration of fo l low-up there was a protect ive 
e f fec t for oestrogen f rom cardiovascular disease with a relative 
risk of death o f 0 . 3 3 . 
Nachtigal l et al (1979) performed a 10-year double-blind 
prospect ive cohort study to evaluate the long-term ef fec t of 
oestrogen replacement on postmenopausal women. Using 84 
matched pairs, half were treated with conjugated equine 
oestrogens 2.5 mg daily and medroxyprogesterone acetate 10 
mg daily for seven days each month. After 10 years there was 
only one myocardial infarct in the treated group whilst there 
were three in the untreated group (relative risk = 0.33). 
The Framingham data have continued to produce 
confl ict ing evidence regarding the effect of oestrogen on the 
cardiovascular system. Wilson et al (1985) studied the effect 
of oestrogen on morbidity f rom cardiovascular disease in 1284 
postmenopausal women aged 50 to 83 years who were 
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par t ic ipa t ing in the Framingham Heart S tudy ' s 12'^ biennial 
examinat ion . They found an elevated risk of cardiovascular 
morb id i ty among women repor t ing pos tmenopausa l oestrogen 
use，particularly among oest rogen users who smoked cigaret tes 
(RR=1.76) . The pos tmenopausa l oes t rogen-use group included 
all women who had ever used pos tmenopausal oest rogens 
during the eight years be fore the 12'^ biennial examinat ion. 
The overal l ever-use rate fo r oestrogen was low (24.4%). The 
Framingham data fur ther suggested that oestrogen use at 
basel ine was less than 15%. 
However , in an at tempt to determine why the Framingham 
data are at such odds with all other data, a number of points 
should be made. Wilson included in his oestrogen-use group 
all women who had ever used oestrogens. These included 
women who had stopped oestrogen therapy as a result of the 
fear of developing cancer even when the oestrogen was taken 
for a short t ime only. Also included in these f igures were 
women who experienced angina without permanent or residual 
coronary artery occlusion or myocardial damage. These women 
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may therefore have been suf fer ing f rom syndrome X and not 
angina. When the Framingham f igures were reanalyzed using 
non-fa ta l myocardial infarct ion and fatal coronary occlusion, 
then the use of oestrogen was associated with a protective 
e f fec t among women aged 50-59 years but had no apparent 
e f fec t in older women. 
Crof t and Hannaford (1989) performed a case-control 
study on data collected during the Royal College of General 
Pract i t ioners ' oral contraception study. The adjusted relative 
risk for acute myocardial infarct ion associated with the use of 
hormone replacement therapy in this study was 0.8. 
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n.F. The Mechanism of Cardioprotection of 
Oestrogen 
Coronary artery disease is the leading cause of death in 
postmenopausal Caucasian women (Philosophe and SeibeI, 
1991). However populat ion studies have clearly shown a major 
benef i t of hormone replacement therapy on the incidence of 
CAD (Knopp et al, 1988). Oestrogen appears to provide 
cardioprotect ion through both indirect and direct mechanisms. 
It is important to understand how estrogen produces these 
effects , both to extend our knowledge into the pathogenesis of 
CAD and to help optimize HRT regimens for the prevention and 
treatment of the disease. The indirect mechanisms have already 
been mentioned and include ef fec ts on the lipid profi le , 
coagulation and f ibr inolysis and insulin resistance. Oestrogen 
also has a direct ef fec t on the vessel wall where it promotes an 
increase in blood flow. These effects will be described in more 
detail in the fol lowing section. 
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II.F.1. The Indirect Effect of Hormone Replacement 
Therapy on the Cardiovascular System 
Oestrogens have at least three d i f fe rent e f fec t s on 
physiologic systems: l ipids and l ipoproteins metabolism, 
carbohydrate metabol ism and the coagulation components of 
atherosclerosis . 
II.F.l.a. The Effect on Lipids and Lipoproteins 
Tradit ionally, HRT has been thought to benefi t the 
cardiovascular system mainly by altering concentrat ions of 
l ipids and l ipoproteins (Bush et al, 1987). Oestrogen has been 
shown to: 
1. Increase the rate of removal of chylomicron remnants by the 
liver. 
2. Increase VLDL-C secretion from the liver. 
3. Increase hepatic uptake of VLDL remnants. 
4. Increase uptake of LDL-C by the up-regulated LDL receptor 
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5. Increase synthesis of apoprotein A-1 
6. Increase bile acid secret ion and hence increase cholesterol 
removal . 
7. Act as an ant ioxidant which protects against l ipoprotein 
oxidat ion and uptake. 
8. Decrease the rate at which LDL-C is taken-up by blood 
vessel walls . 
9. Increase the serum concentrat ion of HDL-C and decrease the 
concentrat ion of TC. 
Whils t oestrogen has anti-atherogenic e f fec ts on lipids 
and l ipoproteins, the addit ion of progestogens to oestrogen 
replacement therapy may negate the effect of oestrogen. The 
more androgenic the progestogen, the greater the opposing 
af fec t on oestrogen. A number of studies have assessed the 
ef fec ts of combined oestrogen-progesterone therapy on 
l ipoprotein metabolism. Progestogens in clinical use can be 
classif ied as 19-nortestosterone derivatives (having high 
androgenic activity) or 17-hydroxyprogesterone derivations 
(having low androgenic activity). In general, 19-
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nor tes tos terone derivat ives oppose the oestrogen-mediated 
e f fec t s on l ipoprotein metabolism, decreasing plasma HDL-C 
and t r iglycer ide concentra t ions and increasing LDL-C 
concentrat ions. The 17-hydroxyprogesterone derivatives have 
relat ively neutral e f fec t s on lipid and l ipoprotein 
concentrat ions. Weinstein et al (1994) examined the use of 
medroxyprogesterone acetate and oestradiol given daily in a 
combined regimen. No d i f fe rences in lipid nor l ipoprotein 
concentrat ions were observed between the 2 treatment groups. 
II.F.l.b The Effect on coagulation and fibrinolysis 
The administrat ion of HRT improves the balance between 
coagulation and f ibrinolysis , result ing in a reduction in the risk 
of thrombosis (Winkler et al, 1978; Gordon et al, 1978; 
Paganini-Hill et al, 1988; Ross, et al, 1990). Oestrogen 
replacement therapy lowers circulating levels of f ibrinogen and 
platelet activator inhibitor and does not appear to increase the 
risk of venous thromboembolism (Lowe et al, 1992). 
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II.F.l.c. The Effect on Insulin and Glucose Metabolism 
Oestradiol reverses insul in res is tance and 
hyper insu l inaemia which tend to occur in pos tmenopausal 
women. Pancreat ic insulin secret ion is increased，and there is a 
decrease in insul in res is tance and an increased insulin 
sensi t ivi ty (Cagnacci et al, 1993; Notelovi tz et a l，1987 ; 
Fowlkes et al, 1995). Insulin res is tance is associated with high 
plasma t r ig lycer ide concentra t ions , low HDL-C, hyper tens ion 
and premature a therosclerosis . 
II.F.2. The Direct Effect of Hormone Replacement 
Therapy on the Cardiovascular System 
In 1987, Bush et al suggested that the cardioprotect ive 
e f fec t of oestrogen was substantial ly mediated through changes 
in the l ipid prof i le . It was estimated that as much as 50% of 
the cardioprotect ion could be explained by lipid changes. 
However in the studies of Adams et al (1987) using a monkey 
model, ethinyl oestradiol was shown to protect the vessel wall 
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f rom the negat ive e f f ec t s of a h igh- fa t diet and the HDL 
choles te ro l - lower ing e f f ec t s of progesterone. Subsequent 
s tudies involving both basic and cl inical research using animal 
models as well as humans have provided good evidence for a 
direct e f f ec t of oes t rogens on the arterial wall (Adams et al, 
1990). Receptors for oest rogen have also been shown to be 
present in the great vessels (McGil l et al, 1989). 
II.F.2.a. The Effect of Oestrogen on Vascular 
Contractility 
Oestradiol has been shown to have a posi t ive inotropic 
e f fec t in animals, increasing cardiac output and causing 
systemic vasodi latat ion (Magness and Rosenfeld 1989). In 
studies of isolated rabbit coronary artery rings, the addit ion of 
increasing doses of oest radiol-17p resulted in progressively 
greater degrees of arterial relaxat ion (Jiang et al，1991). This 
e f fec t was maintained when the vascular endothelium was 
removed, and when inhibi tors of nitric oxide (endothelium-
derived relaxing factor) were added. 
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In addit ion, oophorectomised cynomoIgus monkeys 
fed an atherogenic diet showed a paradoxical vasoconstr ict ion 
of coronary arteries in response to acetylcholine compared with 
the usual endothel ium-dependent coronary vasodilatat ion seen 
in normal animals (Will iams et al, 1990). However, oestrogen 
administrat ion restored the normal vasodilatory response to 
acetylchol ine. Treatment with conjugated equine oestrogens 
have also been found to augment endothel ium-mediated 
dilatat ion of atherosclerot ic coronary arteries in cynomoIgus 
monkeys (Will iams et al, 1994). 
ILF.2.b. The Effect of Oestrogen on Endothelial 
Dysfunction 
Oestrogen receptors have been demonstrated in the walls 
of blood vessels of various primates including man and it has 
been suggested there may be a direct effect of oestrogen in the 
inhibit ion of atheromatous plaque formation. Besides, 
oestrogen can stabilize atherosclerotic lesions and regress the 
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occlus ion (Wiss ler and Vessel inovi tch , 1990; Blankenhorn and 
Hodis , 1994). 
Cons is ten t with this hypothes i s is the fac t that oestrogen 
reduces the format ion of th romboxane (Hussman et al, 1986; 
Adams et a l，1987) . There is reduced smooth muscle 
p ro l i fe ra t ion and an associa ted decrease in the uptake of 
choles terol . Oestrogen is thought to bind to steroid hormone 
receptors in blood vessels including the coronary arteries, 
resul t ing in a decrease in vasoconstr ic t ion and increasing an 
blood f low. Other direct e f fec t s on the blood vessel wall (at 
the level of the arterial int ima) have been demonstrated, 
including al terat ions in collagen and elastin format ion, as well 
as changes in prostacycl in product ion (Adams et al, 1987). 
Oestrogen is also thought to increase the local production 
of prostacycl in , a vasodi latory prostaglandin that also opposes 
platelet aggregation. This is important under condit ions of 
coronary occlusion, when the release of thromboxane induces 
aggregation of platelets . A favourable 
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pros tacyc l in / th romboxane balance, by media t ing increased 
blood f l ow and ant i -aggregat ion, may help explain the 
cardioprotec t ive e f f ec t s of oest rogen. 
The study of Steinlei tner et al (1989) of uter ine vessels in 
pos tmenopausa l and premenopausa l women disclosed a 
substant ia l d i f fe rence in product ion of the stable prostacycl in 
metabol i te 6-keto-Pros taglandin Fia in these two groups of 
women. The product ion in postmenopausal ar ter ies was 
substant ia l ly lower (p < 0.05, Mann-Whi tney U test) than in 
premenopausa l arteries. Prel iminary data also suggest that 
parental oestrogen may increase prostacycl in excret ion in vivo 
and lower the product ion of thromboxane. Oestrogen increases 
endothel ia l product ion of prostaglandin h , a vasodilat ing, 
p la te le t - repel l ing compound and this should also reduce the risk 
of developing atherosclerosis (Fogelberg et al, 1990). 
Oestradiol also appears to act as a calcium antagonist . 
Oestradiol relaxes rabbit coronary arteries that have been 
constr icted by endothelin-1，and also inhibits inward calcium 
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cur ren ts and reduces in t race l lu la r f r ee calc ium in isola ted 
cardiac myocy tes (J iang et a l， 1 9 9 2 " ’ . Calc ium antagonis ts 
have been shown to re tard the development of early 
a the romatous les ions in coronary ar ter ies (Licht len et al, 1990)， 
and oes t rogen has been shown to produce a s imilar e f fec t in 
animals (Wil l iams et al, 1990). The evidence for oes t radiol -
17p act ing as a calc ium antagonis t , in addi t ion to any 
endothe l ium-dependent act ions, is therefore persuas ive (Col l ins 
et al, 1993). 
II.F.2.c. Other Possible Direct Actions of Oestrogen 
Oest rogens are ant ioxidants and appear to protect the 
endothel ia l cell f rom injury due to stress (Negre-Salvayre et al， 
1993; Keaney et al，1994). Recent t issue culture experiments 
have indicated that oestrogens inhibit endothel ial cell 
express ion of adhesion molecules . This act ion may inhibit 
p la te le t aggregation and adhesions seen in the early stages of 
a therosclerosis and may be important in vascular thrombosis 
format ion and tone (Steinbrecher et al，1991). 
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II. G. The Effect of Oestrogen on Blood Flow 
Oestrogen receptors have been demonstra ted in the walls 
of b lood vessels and it has been suggested that there may be 
direct receptor -media ted e f f ec t s of oest rogens on the vascular 
endothel ium, the smooth muscle , and the adventi t ia (Rosano et 
al，1992. These act ions lead to improvement in coronary flow 
reserve or coronary hemodynamic responses to stress, reduced 
risk of damage due to a therosclerosis and prevent ion of 
thrombosis (Sarrel , 1990; Wren, 1989; Brenner et al，1989; 
Vane et al, 1990). 
A number of methods have been used to assess the ef fec t 
of oestrogen on blood f low, one of the commonest being the 
measurement of pulsat i l i ty index (PI) using Doppler ul trasound. 
The PI is an indirect Doppler-derived measurement of 
per ipheral vascular resistance which ref lects resistance to blood 
flow distal to the point of sampling (Gosling et al, 1975). 
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The f i r s t Doppler s tudy on the e f fec t of oestrogen on 
blood flow was that of Bourne in 1990，the PI in the uter ine 
ar ter ies of 10 hea l thy pos tmenopausa l women were measured 
who were t reated with t ransdermal oestradiol and sequential 
oral nore th is te rone acetate. A 50% reduct ion in the PI was 
found over 6-10 weeks of t reatment on this regimen. 
Gangar et al (1991) invest igated the e f fec t of oestrogen 
on PI of the internal carot id artery in 12 postmenopausal 
women. In all 12 pat ients was a s ignif icant negative 
correla t ion between the PI of the internal artery and 
t ransdermal oestradiol therapy (r = - 0 . 7 0 ) . This suggested a 
direct e f fec t of oestrogen on the arterial system. 
The administrat ion of oestradiol to postmenopausal 
women has also been shown to produce an increase in cardiac 
output and forearm blood flow (Ginsburg et al, 1991). 
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Doppler echocardiography studies have shown that 
oest rogens increase both stroke volume and flow accelerat ion in 
the aorta arteries in postmenopausal women through a 
combinat ion of enhanced inotropism and the vasodilatory action 
of oestrogen (Pines et al, 1991). 
Timothy et al (1992), performed study on the e f fec t s of 
progestogen addit ion on arterial tone in the uterine artery of 
postmenopausal women receiving oestrogen therapy. It was 
shown that the mean PI fel l to 53% of its pretreatment value 
within 12 days of oestradiol administrat ion (p<0.0001) but was 
66% of its pretreatment value when a progestogen was 
combined with oestradiol (p<0.005). 
The long term effec ts of HRT on the uterine 
circulation had been evaluated by Jouko et al (1993). They 
found that when HRT was initiated 2 to 10 years after the 
menopause, the uterine vascular resistance did not fall to such a 
low level as was found in those women who had been started on 
HRT earlier. 
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Penott i et al, (1993) conducted a study of blood flow in 
the internal carotid and middle cerebral arteries by measuring 
the PI var iat ions in these arter ies in 25 early postmenopausal 
women during a 6-month course of HRT (transdermal oestradiol 
50 mg/day was given cont inuously and medroxyprogesterone 
acetate 10 mg/day was added for 12 days every second month). 
They found that the PI was s ignif icant ly reduced (p=0.0001) in 
both arter ies af ter 6 weeks and that there was a reduction in the 
PI at 22 weeks. In addition, the cyclical progestational 
supplementat ion did not modi fy the positive ef fec t on the 
reactivi ty of the blood vessels. 
Most recently, an acute reduction in myocardial 
ischaemia has been demonstrated in response to oestradiol 
administrat ion (Rosano et al, 1993). In a double-blind 
crossover study, 11 postmenopausal women with 
angiographically demonstrated CAD were randomized to 
treatment with either sublingual oestradiol-17p or placebo 
before undergoing exercise ECG testing. The administration of 
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oestradiol resul ted in a s ignif icant increase in the time taken to 
produce a 1mm ST segment depression in overall exercise time. 
These studies provide study evidence to suggest that the 




III.A. Formation of Research Hypothesis 
The associat ion between the onset of the menopause and 
the increased risk of developing CAD has al ready been 
described，as has the protect ive e f fec t of the adminis t ra t ion of 
HRT to pos tmenopausal women. However， the mechanisms 
which provide this cardioprotect ion are not yet fu l ly 
unders tood. 
Whils t the favourable e f fec t s of hormone replacement 
therapy on l ipids and l ipoproteins have been studied in detail, 
there are relat ively few data on the direct e f fec t s of oestrogen 
on the cardiovascular system. This thesis will address the 
effect, of hormone replacement therapy on peripheral blood flow 
in postmenopausal women. Previous Doppler flow studies have 
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suggested that the adminis t ra t ion of HRT reduces res is tance in 
vesse ls resu l t ing in an increase in blood f low. Most of these 
s tudies have been pe r fo rmed in ei ther the u ter ine ar ter ies or 
else in larger ar ter ies such as the carot ids or the aorta. 
However these may not have been the most appropr ia te vessels 
to s tudy. The uter ine ar ter ies may not be representa t ive of 
other a r te r ies in the body as their posi t ion in the genital t ract 
could po ten t ia l ly make their response to hormones d i f fe ren t 
f rom that of ar ter ies outside of the genital tract . The carot ids 
and the aorta are of large diameter , and are not good examples 
of res is tance vessels，and fo r these reasons, per ipheral arteries 
will be studied in this thesis . The per ipheral ar ter ies are 
accessible , are of narrow diameter and Anderson et al, (1995) 
found that brachial artery behaved in some ways in a similar 
manner to the coronary arteries. In addit ion, as peripheral 
vascular disease is more common af ter the menopause, the 
abil i ty to demonstrate that the administrat ion of HRT had a 
benef ic ia l e f fec t on peripheral blood f low would provide 
another reason in favour of the use of HRT by postmenopausal 
women. 
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III.B. Research Hypothesis 
The hypotheses of this thesis are: 
(1) That the administration of oestrogen reduces the resistance 
to blood flow in the peripheral vascular system; 
(2) That combined oestrogen-progestogen replacement can 
reduce peripheral vascular resistance. 
In addition, the relationship between the resistance of the 
peripheral arteries and the serum oestradiol concentration will 
also be investigated. Assuming that the peripheral resistance 
changes occur in response to the administration of HR T, it 
would be expected that there would be a negative correlation 
between the serum oestradiol concentration and the 
measurement of peripheral resistance. 
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III.C. Plan of Studies 
III.C.I. Pilot Study 
A pilot study was conducted to assess the feasibility of 
the subsequent randomized trial and to facilitate the calculation 
of sample size of the randomized trial on the research 
hypothesis that HR T can alter the rate of peripheral blood flow. 
The pilot study was an observational one, and the procedures 
were similar to the actual study with a sample size of only 11 
healthy postmenopausal females. By means of Doppler 
ultrasonography the PI of the brachial, radial dorsal peids and 
popliteal arteries was measured prior to HR T treatment and 2 
months after treatment. Details of the pilot study would be 
described in the next chapter. 
111.C.2. Randomized Controlled Study 
The thesis focused on a randomized controlled study 
based on the pilot study stated in the previous section. In order 
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to test the hypotheses in III.B, blood flow will be studied in the 
peripheral arteries of postmenopausal women using Doppler 
ultrasound. Blood flow will assessed using Doppler ultrasound 
examination of the brachial, radial, popliteal and dorsal pedis 
arteries to produce flow velocity waveforms and a measurement 
of the pulsatility indices of these arteries. The pulsatility index 
is an indirect Doppler-derived measurement of vascular 
resistance which reflects resistance to blood flow distal to the 
. point of sampling (Gosling et aI, 1975). This parameter was 
chosen as it is one of the most accepted non-invasive methods 
of measuring the resistance of blood flow and the PI correlates 
well with vascular tone (r>94%) (Legarth et aI, 1990). 
Previous studies have suggested that the administration of HR T 
can be expected to affect blood flow within two months of the 
start of treatment, and in this thesis a duration of six months 
was chosen so that some idea could be obtained of whether 
initial changes in blood flow were maintained with continued 
treatment. To obtain a homogeneous study group and to avoid 
the problem of bleeding on combined HR T, it was planned to 
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recru i t only women who had undergone total abdominal 
hys te rec tomy and bi la teral saIp ingo-oophorec tomy. 
As it was not poss ib le to obtain p lacebo packs of the 
d m g s to be used or to pe r fo rm blind packaging，a prospect ive 
randomized study was chosen wi thout p lacebo control . It was 
p lanned to use three groups，one on no t reatment , another on 
unopposed oestrogen and a third on cont inuous combined 
oest rogen and progestogen. By using a cont inuous ra ther than a 
cycl ical regimen, the e f fec t of the oest rogen/progestogen 
“cycle，，was removed，and this did not need to be considered 
when the blood flow studies were per formed. It was not 
considered hazardous to the pat ients for one group to receive 
cont inuous combined HRT，even though it is more common 
pract ice to give unopposed oestrogens to women who have had 
a hysterectomy. 
The study design will be described in detail in the 




IV.A. Pilot Study 
A pilot study was conducted among postmenopausal 
women f rom the Hormone Replacement Therapy Clinic, Prince 
of Wales Hospital , Hong Kong. New referra ls to the clinic who 
i) were not taking HRT 3 months before the f i rs t visit，ii) who 
agree to commence HRT af ter the f irst visit, were invited to 
part icipate into this observational study. Those who had taken 
HRT within 3 months before the 1st visit or with a history of 
hypertension or cardiovascular diseases, or smoking habits were 
excluded. 
Before treatment each patient had an assessment of PI of 
brachial, dorsal pedis, popliteal and radial arteries. The PI 
which ref lect the peripheral vascular resistance was measured 
by Doppler ultrasound with a 7.5 MHz peripheral vascular 
84 
ul t rasound probe. The pat ients with surgical ly menopause were 
prescr ibed unopposed oestrogen in the form of 2 mg oral 
oestradiol dai ly (Est rofem, Novo Nordisk, Bagsvaerd, Denmark) 
and those with spontaneous menopause were given the same 
drugs and 5 mg medroxyproges terone acetate dai ly for the f i rs t 
12 calendar days of each month (Provera，Upjohn Company, 
MI，USA). Af te r 2 months all pat ients were reassessed for their 
per ipheral vascular resis tance. 
Per ipheral res is tance was measured by the same 
invest igator in a quiet room where light was constant and 
ambient temperature was kept between 21 to 22 °C. Before 
measurement pat ients were fas ted for not less than 2 hours and 
rested in supine posit ion for 15 minutes. Fol low-up studies at 
2 months were performed at a similar time of the day as the 
initial studies performed. 
The changes in PI were tested with Wilcoxon matched-
pairs signed-ranks test. 
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Based on this pilot study, a randomized control led study 
was designed to assess the e f fec t of unopposed oestrogen and 
combined oestrogen on peripheral vascular resistance on 
postmenopausal women. Detai ls of the randomized controlled 
study was described in the fo l lowing sections. 
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IV.B. Study Population 
Par t ic ipants in these s tudies were selected f rom those 
women at tending the Hormone Replacement Therapy Clinic at 
the Pr ince of Wales Hospital , New Terr i tor ies，Hong Kong. 
Based upon the sample size calculat ion (will be described in 
section IV.D), a total of 48 women were invited to take part in 
these studies. All subjects had undergone total abdominal 
hys terec tomy and bilateral sa lpingo-oophorectomy for benign 
gynaecological condit ions. The inclusion cri teria were as 
fol lows: 
1. Chinese race 
2. 35-65 years of age. 
3. Free f rom any hormonal t reatment of any kind for at least 3 
months prior to part icipation in the study. 
4. Free f rom any disease known to af fec t the vascular tree. 
5. Free f rom any drugs known to alter the funct ion of the 
vascular system. 
6. Normal liver funct ion. 
87 
IV.B.1. Recruitment of Cases 
IV.B.l.a. Patients，Consent 
Before the commencement of the study, the nature of the 
study and the anticipated ef fec ts of the treatment were ful ly 
explained to the patients. If they agreed to part icipate, they 
were asked to sign a written consent form (Appendix 1) and to 
comply with their prescribed treatment. 
IV.B.l.b. Method of Recruitment 
At the commencement of the study, a ful l medical history 
was taken and a screening physical examination was performed. 
Laboratory investigations including liver funct ion testing and a 
fast ing blood sugar were taken before the commencement of 
treatment. 
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Subjec ts who agreed to par t ic ipate in the study and who 
met the inc lus ion cri ter ia were randomly al located to one of 
three groups. These groups were chosen to examine changes in 
per iphera l blood f low in pos tmenopausal women taking either 
unopposed oral oestrogen or oral oestrogen combined with a 
progestogen in a cont inuous combined form of HRT. A control 
group us ing no t reatment was also included. 
The random allocat ion was per formed using computer 
generates random numbers. 
Group 1: No treatment (controls) 
Group 2: Oral oestradiol (Estrofem, Novo Nordisk，Bagsvaerd, 
Denmark) 2mg daily at the same time each day. 
Group 3: Oral oestradiol 2mg and norethis terone acetate lmg in 
a sequential pack (Kliogest, Novo Nordisk, 
Bagsvaerd, Denmark) one tablet at the same time 
each day. 
IV.B.l.c. Research Methodology 
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Blood flow studies were pe r fo rmed at the t ime of 
recru i tment and a f te r 2, 4 and 6 months of t rea tment . At each 
examinat ion , measurements of blood flow were made in 4 
per iphera l ar ter ies (brachial , radial , dorsal pedis and popl i tea l ) 
using methodology to be prescr ibed later in this sect ion. 
Approximate ly 8 ml of blood was drawn at each visit and was 
sent to the Chemical Pathology Laboratory of the Pr inces of 
Wales Hospi ta l for the measurement of concent ra t ions of serum 
oestradiol . 
Within this period, any drop-outs or exclus ions f rom the 
study were recorded and the reasons marked down. 
IV.C. Ethical Considerations 
In this study，some women were selected to receive no 
treatment , and others were prescribed progestogen in addition 
to oestrogen. The usual prescribing practice is that women who 
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are menopausa l and who have had a hys te rec tomy receive 
unopposed oes t rogen. The commonly held v iew is that the 
addi t ion of a proges togen is of no benef i t in the absence of a 
uterus，and that it may in fac t in te r fe re with the act ions of 
oes t rogen. 
It was not thought that the fa i lure to give oestrogen for a 
per iod of 6 months (control group) would have a s ignif icant 
de le ter ious e f fec t on the heal th of these women. Measurable 
reduct ions in bone mineral densi ty are not usual over a period 
of 6 months off t reatment , and it was not thought that there 
would be an increase in cardiovascular r isk of cl inical 
s ignif icance wi thout oestrogen over a period of 6 months. 
In addit ion， i t was not thought that the addit ion of a 
progestogen for 6 months would have a negative long term 
ef fec t in terms of reducing the benef ic ia l e f fec t of oestrogen on 
the lipid prof i le . 
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Both Es t ro fem and Kliogest have been approved fo r the 
t rea tment of pos tmenopausa l women in Hong Kong, and 
recommended doses of these drugs were used. 
At the complet ion of the study, all subjec ts were to be 
re fer red back to the Hormone Replacement Clinic where they 
could receive HRT in the same manner as other pat ients . 
The protocol was approved by the Clinical Research 
Ethics Committee of the Chinese Universi ty of Hong Kong. 
IV.D. Sample Size Calculation 
Based upon the pilot study the sample size required to 
detect a mean reduction in the pulsat i l i ty index with treatment 
of 7.4 士 3.7 compared with a mean change of 0 in the control 
group was 8 cases in each group (P = 8 0 %， a = 0.05). To 
overcome any possible error in the estimation of sample size 
and to allow some loses in cases, 8 extra cases were recruited. 
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Therefore the total sample size estimated for each group was 
16. 
IV.E. Statistical Analysis 
All data were stored in a personal computer (IBM-PC 
compatible, with Intel 80486) and the results were analyzed 
using the Statistical Package for Social Science (SPSS, 
Chicago, IL). The Wi lcoxon ' s Test for paired observations was 
used to compare the changes in blood flow parameters within 
study groups, and Kruskal-Wallis 1 way Anova was used to find 
out the d i f ferences between groups. They included differences 
in age, length of time af ter surgery, PI at recruitment. The 
correlation between the resistance of peripheral blood f low and 
the serum concentration of oestradiol was analyzed by using 
Mann-Whitney Test. 
IV.F. Physical principles of the measurement of 
peripheral resistance 
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The Doppler e f fec t is a change in the f r equency of echo 
signals that occurs whenever there is relat ive motion between 
the sound source and the ref lec tor . The pr inciple is stated in 
approximate mathemat ical form: 
f D = 2fOvcosG/c Equat ion (1) 
where f D is the Doppler f requency shif t , fO is the incident 
f requency , v is the flow veloci ty, c is the speed of sound in 
t issue, and G is the angle between the ul t rasound beam and the 
flow direct ion. This expression implies that the f requency of 
an ul t rasound echo f rom a moving ref lector d i f fe r s f rom the 
f requency of the incident sound wave. The so-called Doppler 
shif t f requency f D depends on the velocity of the ref lec tor and 
its direction，assuming that the incident f requency and sound 
velocity are constant for a given measurement. 
In principle, it is possible to estimate the velocity of a 
moving object emitting or ref lect ing sound (or an ultrasound 
wave) f rom the measured Doppler shif t by solving Equation (1). 
However, in applying this principle to the measurement of in 
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vivo blood flow by means of u l t rasound in the low-megaher tz 
f r equency range, the simple express ion above does not account 
for a number of non- ideal e f f ec t s that, in pract ice , compromise 
the accuracy of veloci ty est imates. Factors l imit ing the use of 
Doppler u l t rasound in local iz ing and measur ing blood flow 
include the interact ion of ul t rasound with t issue and blood, 
t ransducer per formance , t ransmit ted signal character is t ics , and 
received signal processing methods. 
The choice of f requency for a Doppler examinat ion is 
inf luenced by a number of factors . For cont inuous wave 
techniques , the primary considerat ion is f requency-dependent 
at tenuation. Since at tenuation increases with f requency, high 
f requencies (10 MHz and above) can be used for the peripheral 
circulat ion, where the t issue path is small. To detect flow in 
deeper vessels, lower f requencies must be used. The choice of 
center f requency in pulse Doppler measurement is a 
compromise between higher f requencies at which there is 
improved resolut ion and increased amplitude of the returned 
Doppler signal versus at tenuation，which imposes limits on 
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image depth. A fu r the r problem is that of a l ias ing, which will 
be d iscussed in detai l later. 
Refe r r ing again to Equat ion (1)，the angle of insonat ion 
s trongly a f f ec t s the Doppler shif t . When the u l t rasound beam 
is at r ight angles to the vessel (cos 90° = 0)，the Doppler shif t 
f r equency is theore t ica l ly zero and no signal wil l be obtained. 
In pract ice , some divergence of the beam occurs so that a small 
signal is obtained. Never theless , at angles approaching 90°，the 
abil i ty to discr iminate between forward and reverse flow is 
impaired. Typical ly at such angles, both posi t ive and negative 
Doppler sh i f t s are detected，appearing equally above and below 
the ze ro- f low line in a spectrum analyzer trace. Angles 
exceeding 60° are unsui table for quant i ta t ion of f low, since the 
rate of change of the cosine func t ion increases rapidly toward 
90。，so that small errors in angle measurement cause large 
errors in angle-corrected veloci ty computat ions (Gill，1979). 
This presents a problem, since for many vessels of interest in 
Doppler studies such as the portal vein and the umbilical vein, 
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the only avai lable acoust ic window f requen t ly p laces the 
t ransducer at near ly r ight angles to the vessel . 
When the t ransducer is al igned with a vessel (cos 0® = 1)， 
the largest Doppler shi f t wil l be obtained and angle uncer ta inty 
has its least e f fec t . Howeve r， t he r e may be technical 
d i f f icu l t i es in obtaining signals at such narrow angles because 
of total re f lec t ion of sound waves at the vessel wall . For these 
reasons, angles between 30° and 60° are usual ly employed. 
However , if one is merely t rying to establish the presence of 
f low in a vessel , then the angle is not cri t ical . 
IV.F.1. The Arterial Analogue Waveform 
The flow pattern in the main arteries of the upper or 
lower extremit ies normally have three components or phases 
during each cardiac cycle. The f i rs t phase has the highest 
Doppler f requency and is the large, forward velocity peak 
produced by cardiac systole. The second phase is a brief phase 
of flow reversal in early diastole and the third is a low-
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f requency phase of forward f low in late diastole. This tr iphasic 
flow pat tern is modif ied by various factors , one of the most 
important being peripheral vascular resistance. 
IV.F.2. Peak Systolic Velocity 
With a progressive increase in the severity of arterial 
stenosis, the f irst parameter to become abnormal is the peak 
velocity in systole. The systolic velocity r ises smoothly in 
inverse proport ion to the severity of stenosis. This parameter 
bears a wel l-defined relat ionship to the magnitude of luminal 
narrowing. However, the peak systolic velocity does not 
continue to rise to the point of luminal occlusion; instead, 
maximum velocities occur with a lumen diameter of 1 to 1.5 
mm. As the lumen narrows beyond that point, the systolic 
velocity decreases because of the effects of f low resistance. 
In a study by Kohler and colleagues (Kohler et al, 1986) 
peak systolic frequency measurements were found to be highly 
consistent from one examiner to another, but a moderate peak 
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f requency variat ion was noted in the same pat ient on d i f ferent 
examinat ions. This variabil i ty was attr ibuted to changes in 
cardiovascular physiology f rom one examination to another. 
Blood pressure, pulse rate, cardiac output, peripheral 
resis tance, and arterial compliance may all a f fec t the carotid 
systolic veloci t ies in normal individuals and patients with 
stenosis. In a hypertensive patient, stenotic velocit ies are 
likely to be higher than in a normotensive individual with the 
same degree of narrowing. Conversely, a diminished cardiac 
output reduces both the systolic velocit ies associated with a 
stenotic lesion. 
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IV.G. Measurement ofPulsatiIity Index 
Figure IV.1. The pulsatility index 
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Because the magnitude of the Doppler shif t is directly 
proportional to the cosine of the beam-to-vessel angle, 0, as 
discussed above, a direct quantitative analysis of the velocity 
waveform requires a value for this angle. Accurate 
measurement of the beam-to-vessel angle is diff icul t with 
simple, hand-held Doppler equipment; however, quantitative 
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data can still be obtained by using rat ios of Doppler shi f ts that 
are independent of the beam-to-vessel angle. One such rat io is 
the pulsat i l i ty index (PI), which is calculated by dividing the 
peak-to-peak f requency d i f ference by the mean frequency. 
Measurements for calculat ing PI can be based on either 
analogue waveforms or the output of a spectrum analyzer. The 
use of analogue waveforms has been crit icized on the grounds 
that they may contain errors and art ifacts . Nonetheless , there 
is a close correlation between the reduction in PI and the 
severity of arterial occlusive disease as assessed by 
arter iography and ankle pressure measurement. The PI is a 
sensitive index of diastolic runoff . With increased peripheral 
vasodilatat ion, diastolic runoff is expected to increase and PI to 
decrease. 
Throughout the study, the same investigator was 
responsible for the examination of the process to minimize 
errors arising from interpersonal differences. The data was 
collected at a similar time in the early afternoon. 
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A colour duplex Doppler ul t rasound (Aloka S-680) with a 
steered 7.5 MHz peripheral vascular ul t rasound probe (Aloka 
UST-5518-7 .5) was used to measure the PL Other equipment 
used included: 
• A mercury- in-bulb thermometer to measure the ambient 
temperature. 
• A skin probe thermometer: DUOTEMP T m l 0 1 
• An automatic sphygmomanometer: CRITKON, DINAMAP 
The target data (peripheral blood flow) can be affected by 
ambient temperature, food intake and the presence of noise. 
Thus, all investigations were carried out under a steady 
controlled environment to eliminate unreliable elements 
introduced by those extrinsic factors. 
Room temperature was maintained constantly between 21° 
C and 22® C. Its reading was obtained from a long standard 
mercury thermometer. The room was air-conditioned with all 
windows closed to prevent draught. Also, noise from outside 
102 
was hardly not iceable inside the experimental room. The room 
was well lit and the l ighting intensity was similar throughout 
the study. 
At each visit , subjects were advised to wear similar 
clothing and eat a similar meal two hours beforehand. In the 
room used for these studies, a comfortable bed and pi l lows 
were provided so that the subjects could lie flat in a supine 
posi t ion. 
The four arteries on the right side of the body were 
examined in a longitudinal plane. The peripheral vascular 
ul t rasound probe was placed in the fol lowing posi t ions to take 
measurements:-
* 
1. B r a c h i a l a r t e r y : at the cubical fossa 
2. R a d i a l a r t e r y : 1cm above the proximal transverse crease. 
3 Dorsa l i s pedis a r t e r y : at the level of insertion of the tibialis 
anterior tendon. 
4. Popl i t ea l a r t e r y : at the popliteal fossa. 
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For the measurement of the f i rs t three arteries, the 
subjects were in a supine posit ion. Before the measurement of 
the popli teal artery, the subjects had to change to a lef t lateral 
posit ion. 
The probe was placed perpendicular to the arteries, with 
as little pressure exerted as possible. It was then rocked 
slightly f rom right to lef t so as to locate the central part of the 
artery. The angle of inclination was set as low as possible to 
obtain the most accurate measurement (below 60°). B-mode 
ultrasound was used to ident i fy each artery. 
All blood flow measurements were performed by an 
investigator who had no knowledge of the treatment plan of the 
individual patients. The outline of each artery was seen on the 
screen and the equipment was then turned to the B/PW mode. 
The cursor was shifted to the central part of the artery and the 
angle of inclination of the probe was adjusted. Then, when at 
least three consecutive waveforms of adequate quality were 
( 
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visible (in PW mode), a hard copy of the image was made af ter 
f reezing the image. 
Peak Flow Velocity (PFV) was traced f rom three 
consecutive waveforms of adequate quali ty on a f rozen image, 
and the Pulsat i l i ty Index (PI) of each waveform was calculated 
with the spectrum analyzer. The PFV and PI used in study 
were obtained by taking the average of three estimated data. 
The PI of the artery was calculated by averaging the PI of 
the three waveforms. 
PI = PI(waveform 1) + PI(waveform 2) + PI(waveform 3) 
3 
IV.G.1. Establishment of Methodologies Used to Measure 
Peripheral Blood Flow 
Before the commencement of the study, 3 female 
volunteers were recruited for the investigation of the influence 
of skin temperature on of peripheral blood flow. Data was 
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collected twice f rom the measurement of their radial arteries by 
Doppler ul t rasound. The object ive of these measurements were 
to determine the relat ionship between skin temperature and 
peripheral blood flow. This could be considered when the f inal 
data were analyzed if s ignif icant changes in temperature had 
been observed. 
Skin temperatures of the right palm and plantar surface of 
the foot were measured with a skin temperature probe 
(DUOTEMP TM 101). The aim was to maintain skin 
temperature within 1° C during the study period. An automatic 
device (CRITKON, DINAMAP, Vital Signs Monitor 1846sx) 
was used to measure pulse rate and blood pressure. 
« 
To ensure that a steady state had been reached before the 
measurement of blood flow, two sets of data were obtained at 5 
minute intervals until the pulse rate and blood pressure varied 
by less than 5 beats/min and 5mmHg respectively. 
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The data for the 4 subjects was f irst collected by one 
investigator and then repeated by another. To determine the 
interobserver rel iabil i ty in the assessment of PFV and PI, all 
results were obtained by calculat ing the average of three sets of 
data. The standard errors were compared to check the 
reliabil i ty. 
IV.G.2. Training of the investigator 
Before the examination of the subjects, the investigator 
had to be familiar with the operation of Doppler ultrasound 
equipment, the choice of the optimal window for examination 
and the angulation for each subject and the necessary 
adjustment in the equipment. The reproducibil i ty of the 
Doppler measurements was tested before the commencement of 
the study. The investigator measured the PI of the brachial 
artery on a volunteer 10 times, 10 minutes apart, under the 
conditions described in Section IV.F. The mean of the PI was 
3.24 士 0.15 (range 2.99 - 3.48). 
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IV. H. Assay for Serum Oestradiol 
Serum oestradiol concentrat ion was tested with 
Micropart iclel Enzyme Immunoassay (MEIA) (Abbot 
Laboratories, USA) in the Department of Chemical Pathology, 
Prince of Wales Hospital . 
IV.H.1. Principles 
1. Micropart icles coated with rabbit anti-oestradiol polyclonal 
antibody were incubated with samples to form an antibody-
oestradiol complex. 
2. An aliquot of the reaction mixture containing oestradiol 
bound to the anti-oestradiol coated micropart icles was 
transferred to the glass f ibre matrix. Thus, the microparticles 
binded irreversibly to the glass f ibre matrix. 
3. Unbound material was removed by washing the matrix. 
4. The oestrogen-alkaline phosphatase conjugate was dispensed 
onto the matrix and binds to the unoccupied antibody 
binding sites. 
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5. The matr ix was washed again to remove unbound material . 
6. The substrate, 4-methylumbel l i feryl phosphate was added to 
the matr ix and the fluorescent product was measured by 
MEIA optical assembly. 
IV.H.2. Reagents 
The reagents (Abbot Laboratories, USA) include reagent 
pack, calibrators, controls and diluent. 
IMx Oestradiol Reagent Pack, (No. 2215-22) 
Anti-oestradiol (rabbit, polyclonal) coated micropart icles in 
BIS-TRIS buffer with protein stabilizers. Preservative: 
contains sodium azide. 
Oestrogen: alkaline phosphatase conjugate in BIS-TRIS buffer 
with protein stabilizers. Minimum concentration: 1 jiig/mL. 
Preservative: contains sodium azide. 
4-methylumbell iferyl phosphate, 1.2 mM， in AMP buffer . 
Preservative: contains sodium azide. 
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Buffer containing surfactant . Preservative: 0 .1% kathon. 
Imx Oestradiol Mode 1 Calibrator 
Mode 1 Calibrator (C). Concentrat ion: 250 pg/mL oestradiol in 
TRIS buf fe r with protein stabilizers. Preservative: contains 
sodium azide. 
IMx Oestradiol Calibrators (No. 2215-02) 
Six bott les of IMx oestradiol calibrators contain 
oestradiol prepared in TRIS buffer with protein stabilizers to 
yield bottle A to F with oestradiol concentration of 0, 50, 250, 
750, 1500 and 3000 pg/mL respectively. Preservative: contains 
sodium azide. 
IMx Oestradiol Controls (No. 2215-12) 
Three bottles of IMx oestradiol controls contain 
oestradiol prepared in TRIS buffer with protein stabilizers to 
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yield low (L), medium (M) and high (H) controls of oestradiol 
concentra t ion of 150’ 500 and 1125 pg/mL). Range: L: 95 -
205，M: 355 “ 645 and H: 820-1430 pg/mL. Preservat ive: 
contains sodium azide. 
IMx Oestradiol Specimen Diluent (No. 2215-50) 
IMx oestradiol specimen diluent , human serum. Preservat ive: 
contains sodium azide. 
To convert control ranges to the units (pmol/L)， the 
fo l lowing calculat ion was performed: 
Concentrat ion in pmol/L = Concentrat ion in pg/mL X 3.67 
IV.H.3. Sample Dilution 
When specimen concentrat ion was greater than 3000 
pg/ml，the specimen was diluted 1:10 with the IMx oestradiol 
specimen diluent before being pipetted into the sample well. 
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The concent ra t ion was calculated by mul t ip ly ing the 
concent ra t ion of the di luted sample by the di lut ion factor . 
IV.H.4. Calibration 
A cal ibrat ion curve was establ ished by tes t ing bot t les A 
to F of oestradiol cal ibrators in duplicate. To evaluate the 
cal ibrat ion curve, low, medium and high controls were also 
tested. The cal ibrat ion curve was stored and subsequent assays 
were tes ted with the mode 1 cal ibrator . 
IV.H.5. Quality Control 
The quali ty control of the assay was secured by the low， 
medium and high controls. When any one of these controls was 
out of i ts specif ied range，the assay should be recal ibrated. 
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IV.H.6. Assay Validation 
The reproducibi l i ty of the assay determined by Abbot 
Laborator ies was shown in table IV.1. 
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Table IV.1. Reproducibility of the IMx Oestradiol Assay 
Source: Adapted from IMx Oestradiol Assay Insert, Abbot Laboratories. 
Mean value Within Run Between Run Total Run 
(pg/mL) "SD CV(%r SD | CV(%) S D � C V ( % ) 
67 7.0 10.4 10.7 16.0 12.8 19.1 
HO ^ ^ 1 ¥A ^ n^ ^ ~ 
^ T9J O 22A 4l ^ 5 J ~ 




V.A. Pilot Study 
There were 11 cases recruited in the pilot study and all 
cases were fol lowed at 2 months. The mean age of the patients 
was 42 (土 2.3) (S.E. of mean) years and the mean duration 
before recruitment was 1.5 (土 0.4) years. Four patients with 
surgical menopause were treated with unopposed oestrogen and 
the remaining 7 patients with natural menopause were treated 
with combined cyclical HRT. 
Table V.1 summarizes the results of the pilot study. The 
PI of brachial artery and radial artery were reduced 
significantly from 10.1 土 3.1 to 5.0 土 0.8 (p < 0.05) and 16.5 土 
4.1 to 4.8 土 4.0 (P < 0.05) respectively. 
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The other ar ter ies studied showed a similar trend but did 
not reach statist ical s ignif icant . There was no d i f ference 
s ignif icance in the mean of PI between those receiving 
unopposed HRT and those using combined cyclical HRT. 
116 
Table V.1 The PI of the 4 peripheral vessels measured 
before and 2 months after treatment 
Brachial Dorsal “ P o p l i t e a l ~ “ R a d i a l ~ 
artery Pedis artery artery artery 
Mean (土 Mean (土 S.E. Mean (土 S.E. Mean (士 
S.E. of of mean) of mean) S.E. of 
mean) mean) 
Pre- 10.1±3.1 21.9±3.7 1 3 . 0 ± 2 . 2 ~ 16.5土4.1 
treatment 
2 5 . 0 土 0 . 8 * 14.5 ± 2 . 8 ~ 9 .8 t0 .8 4 . 8 土 1 . 2 * 
months 
* denotes p < 0.05 compared with pretreatment values 
Wilcoxon matched-pairs signed-ranks test 
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V.B. Study Population 
As previously stated, three groups were used in the 
studies on the e f fec t of HRT on peripheral blood flow in 
postmenopausal women. Group 1 acted as controls and had no 
treatment. whilst those in Group 2 received unopposed 
oestrogen (oral oestradiol 2 mg daily). Those in Group 3 were 
treated with continuous combined oestrogen and progestogen 
(oral oestradiol 2 mg and noresthisterone acetate 1 mg daily in 
a sequential pack). 
Forty-eight patients who underwent total abdominal 
hysterectomy and bilateral salpingo-ophorectomy at the Prince 
of Wales Hospital, Shatin, Hong Kong were recruited and 
completed the 6-month study period. All of those in the 
treatment groups were asked about their compliance with 
medication. All patients gave the positive answers. The PI of 
the peripheral arteries (brachial, dorsal pedis, popliteal and 
radial arteries) was measured at each visit and blood was taken 
to determine the oestradiol concentration on each occasion. 
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Two pat ients were lost to fo l low-up: one before 2 months and 
the other between 2 and 6 months. Of these 2 patients, one did 
not want to continue because of personal d i f f icul t ies in 
adhering to the fol low-up visits. The other pat ient did not want 
to continue treatment because of a fear of developing breast 
cancer. Five cases were excluded f rom the study. One was 
f rom the Group 1 and was excluded because of high oestradiol 
concentrat ion of 1500 pmol/1 at the f i rs t fo l low up visit. This 
was not compatible with postmenopausal state and might have 
been due to an exogenous supplement. Two f rom Group 2 and 
two f rom Group 3 were excluded because the serum oestradiol 
concentrat ion was still in the postmenopausal range, this 
suggested that the patients may not have taken the drugs as 
prescribed. 
119 
V.B.1. Characteristics of the Patients at Recruitment 
The charac ter i s t ics of the s tudy pat ients are summarized 
in Table V.2. The age， the durat ion of menopause and the 
pulsa t i l i ty index in the four ar ter ies were compared using 
Kruska l -Wal l i s 1 -Way Anova. Group 1 consis ted of 16 women 
aged 36 to 51 years (44.9 土 1.0) (mean 土 S.E. of mean ). Group 
2 comprised 16 women aged 37 to 50 (43.9 ± 0.9 years) . Group 
3 included 16 women aged 38 to 54 years (mean 45.0 土 1.1). 
There was no s ignif icant d i f fe rence in the mean age of the 
pat ients between the 3 groups (p = 0.67). All 3 groups included 
pat ients who had undergone a surgical menopause at least 3 
months before the procedure (0.46 土 0.02 years) . No pat ients 
had undergone their surgical procedure more than 1 year 
previously. The duration of surgical menopause in Group 1 was 
0.49 土 0 .04 years. In Group 2 it was 0.48 土 0.06 years and in 
Group 3 0.41 土 0.03 years. Likewise, there was no signif icant 
d i f fe rence in the duration of surgical menopause between the 3 
groups (p = 0.55). There was also no s ignif icant d i f ference 
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between the 3 groups in the basel ine pulsat i l i ty indices in all 
four ar ter ies (P > 0.05). 
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Table V.2.: The characteristics of patients at recruitment 
G r o u p 1 G r o u p 2 G r o u p 3 p 
(No treatment) (Oral (Oral 
oestrogen) combined 
( M e a n 土 treatment) 
S.E. of (Mean 士 （Mean � 
mean) S,E. of S.E. of 
mean) mean) 
Age 44.9士 1.0 43.9士 0.9 45.0 土1.1 N. S. 
(year ) 
Duration 0.49 土 0.04 0 .48± 0.06 0.41 ±0.03 N.S . 
of surgical 
menopause 
_ ( y e a r ) 
PI of 9.25土 1.55 7.75 土 1.55 7.85 土0.65 N. S. 
b r ach i a l 
a r t e r y 
PI of 1 8 . 9 ± 3.6 24.9 ± 7 . 8 21.3 1 4 . 0 N . S . 
dorsa l 
pedis 
a r t e r y 
PI of 13.4 土 1 .6~~13.1 ±2 .4""^16 .0 1 4 . 2 N. S. 
popl i teal 
a r t e r y 
PI of 6 . 8 3 t l . l 7 7.44 1 1 . 3 1 8.78 1 1 . 8 9 N . S . 
r ad ia l 
a r t e r y 
Kruskal-Wallis 1-way Anova 
N. S.: no significant 
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V.B.2. Doppler Measurements 
The means of the pa i red d i f f e rences in the pulsat i l i ty 
indices of the 3 groups a f te r 2 months were compared using the 
Wi lcoxon Matched-Pai rs Signed-Ranked Test. A summary of 
the means of the paired d i f f e rences in the PI of the four ar ter ies 
a f te r 2 months is shown in Table V.3. In Group 1 the means of 
the pai red d i f fe rences in the pulsa t i l i ty indices of the brachial 
artery, dorsal pedis artery, popl i teal artery and radial artery 
were - 2 . 5 5 士 1.55 (p = 0.12)，-3.75 土 4 .09 (p = 0.28)，-1.52 土 
2.18 (p 二 0.61) and - 1 . 1 5 土 0.70 (p = 0.11) respect ively. In 
Group 2, however , three out of four ar ter ies showed s ignif icant 
reduct ion in the pulsat i l i ty index af ter 2 months. The means of 
the paired d i f fe rences of the brachial artery, dorsal pedis 
artery, popl i teal artery and radial ar ter ies were - 3 . 3 5 土 1.70 (p 
< 0.05)，-14.22 土 7.51 (p < 0.05), - 6 . 1 3 土 2.22 (p < 0.001)，and 
- 2 . 8 0 土 1.53 (p = 0.15) respect ively. The only artery in which 
there was no statistical s ignif icance was the radial artery. In 
Group 3，two of the four arteries showed signif icant decrease in 
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the pulsat i l i ty indices af ter 2 months (brachial artery -2.12 土 
0.76 (P < 0.05) and dorsal pedis artery - 4 . 1 1 土 9.22 (p < 0.05). 
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Table V.3.: Mean of the paired difference in the 
pulsatility index after 2 months of hormone replacement 
therapy 
Brachial Dorsal pedis Popliteal Radial 
artery artery artery artery 
(Mean 土 S.E. (Mean 土 S.E. (Mean 土 S.E. (Mean 士 S.E. 
of mean) of mean) of mean) of mean) 
Group 1 
(No —2.55土 1.55 - 3 . 7 5 土 4 .09 - 1 . 5 2 土2.18 - 1 1 5 土 
t r e a t m e n t ) ^ — 
0 .70 
Group 2 
(Oral 一 3 . 3 5土 1 . 7 0 * — 1 4 . 2 2士 7 . 5 1 * — 6 . 1 3 ± 2 . 2 2 * _ 2 8 0 + 
oes trogen) — 
1.53 
Group 3 
(Oral - 2 . 1 2 士 0 . 7 6 * - 4 . 1 1 土 9 . 2 2 * - 4 . 8 3 士 4 . 7 3 —1 6 6 + 
» • • X • \y x^  ^^ 
combined 
t rea tment ) 1 4 0 
Wilcoxon Matched-Pairs Signed-Ranks Test 
*: p<0.05 compared with pre-treatment pulsatility index 
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Table V.4. shows the d i f f e r ences in PI a f t e r 4 months of 
the s tudy per iod. There were no s igni f icant d i f f e rences in the 
PI of any ar ter ies in Group 1 a f te r 4 months . The paired 
d i f f e rences of the PI in the brachia l artery，dorsal pedis artery, 
popl i tea l ar tery and radial ar ter ies were - 2 . 5 4 土 1.65 (p = 
0 .20)， -7 .56 土 3 .27 (p = 0 . 0 6 )， - L 5 7 土 2 .37 (P = 0 .44) and — 
1.50 土 0 .87 (p = 0.28) respect ively . In Group 2，the means of 
PI of the dorsal pedis ar tery ( - 1 7 . 0 2 土 8.13) (p < 0.05) and 
popl i tea l artery ( - 5 . 2 6 土 2 .34) (p < 0.05) showed s ignif icant 
reduct ion. The change of PI in the brachial ar tery which was 
present a f te r 2 months did not pers is t a f te r 4 months (p = 0.18). 
In Group 3 only one artery (brachial ar tery) showed a 
s ignif icant d i f fe rence in PI (p < 0.01). The change of PI in the 
dorsal pedis artery in Group 3 af ter 2 months was s ignif icant 
but there d i f fe rence was not present a f te r 4 months (p = 0.53). 
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Table V.3.: Mean of the paired difference in the 
pulsatility index after 2 months of hormone replacement 
therapy 
Brachial Dorsal pedis Popliteal Radial 
artery artery artery artery 
(Mean 土 S.E. (Mean 土 S.E. (Mean 土 S.E. (Mean 土 
of mean) of mean) of mean) S.E. of 
mean) 
Group 1 
(No - 2 . 5 4 土 1 . 6 5 - 7 . 5 6 .土 3 . 2 7 - 1 . 5 7 士 2 . 3 7 - 1 . 5 0 士 0 . 8 7 
t r e a t m e n t ) 
Group 2 
(Oral — 2 . 1 6 土 1 . 7 3 — 1 7 . 0 2 士 8 . 1 3 * — 5 . 2 6 ± 2 . 3 4 * - 1 9 8 土 1 7 6 
oes trogen) 
Group 3 
(Oral - 2 . 4 6 土 0 . 6 8 * — 4 . 1 3 ± 6 . 4 3 —4.77 士 4 . 6 6 - 3 . 4 9 土 2 . 1 4 
combined 
t rea tment ) 
Wilcoxon Matched-Pairs Signed-Ranks Test 
*: p<0.05 compared with pre-treatment pulsatility index 
127 
The d i f f e rences in the PI a f te r 6 months are shown in 
Table V.5. There were no s ignif icant d i f fe rences in the PI a f te r 
6 months in Group 1. The paired d i f fe rences of the PI in the 
brachia l ar tery, dorsal pedis artery, popl i teal ar tery and radial 
ar ter ies were - 3 . 4 0 土 1.82 (p = 0.07)，-4.59 土 4 .48 (p = 0.41)， 
- 2 . 4 9 士 2 .08 (p = 0.23) and - 1 . 8 2 土 1.23 (p = 0.15) 
respect ively . In Group 2, the dorsal pedis ar tery ( - 1 5 . 2 7 土 
8.25) (p < 0.05) and popli teal artery ( - 4 . 0 3 土 2 .14) (p < 0.05) 
showed s ignif icant reduct ion in the PI. In Group 3， the 
brachial artery still showed s ignif icant reduct ion at 6 months (p 
< 0.01). 
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Table V.3.: Mean of the paired difference in the 
pulsatility index after 2 months of hormone replacement 
therapy 
Brachial Dorsal pedis Popliteal Radial 
artery artery artery artery 
(Mean 土 S.E. (Mean 土 S.E. (Mean 土 S.E. (Mean ± 
of mean) of mean) of mean) S.E. of 
mean) 
Group 1 
(No - 3 . 4 0 ± 1 . 8 2 - 4 . 5 9 士 4 . 4 8 - 2 . 4 9 ± 2 . 0 8 - 1 . 8 2 土 1 . 2 3 
t r e a t m e n t ) 
Group 2 
(Oral _ o . 7 2 土 0 . 8 7 - 1 5 . 2 7 土 8 . 2 5 * - 4 . 0 3 土 2 . 1 4 * _ 3 4 5 � � 6 4 
oes trogen) 
Group 3 
(Oral — 2 . 3 5士 0 . 6 1 * — 8 . 6 7 ± 5 . 2 0 - 4 . 5 6 ± 4 . 4 5 —3.29 土 1 . 8 3 
combined 
t rea tment ) 
Wilcoxon Matched-Pairs Signed-Ranks Test 
*: /7<0.05 compared with pre-treatment pulsatility index 
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Figures V.1. to V.4. i l lustrate the changes in PI in the 
brachia l ar ter ies , dorsal pedis ar ter ies，popli teal ar ter ies and 
radial ar ter ies in the 3 groups. In all groups, the PI of all 
ar ter ies was reduced as compared with pre- t rea tment values and 
the extent of the decrease of PI at 2 months was greater than 
that at 4 month and 6 month. In additon, more arter ies showed 
s ignif icant reduct ion at 2 months than at 6 months . In other 
words, there was slightly increase in PI at 4 and 6 month. 
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V.B.3. Pulsatility Index and Serum Oestradiol 
The relat ionship between the serum oestradiol 
concentrat ion and the pulsat i l i ty indices in each of the four 
vessels studied is summarized in Table V.6. The PI was 
s ignif icant ly lower in those with higher oestradiol levels in all 
arteries [brachial artery (5.64 士 0.30，p < 0.01), dorsal pedis 
artery (12.24 土 0.96，p < 0.01), popli teal artery (9.68 土 0.49，p 
< 0.01) and radial artery (5.50 士 0.42, p < 0.05)]. 
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Table V.6. The relationship between the pulsatility 
indices of the four peripheral arteries and the serum 
oestradiol level. 
Serum Serum p 
oestradiol < oestradiol > 
360 pmoi/1 360 pmol/1 
(mean 土 S.E. of (mean 士 S.E. of 
mean) mean) 
PI of brachial 
a r t e r y 7,23土 0.35 5.64 ± 0.03 0.0012 
PI of dorsal 
pedis a r t e r y 12.41土 0.70 9 . 6 8 ± 0.49 0.0063 
PI of popliteal 
a r t e r y 16.66士1.18 12.24± 0.96 0.0082 
P I of r a d i a l 






It is well documented that hormone replacement therapy 
(HRT) has a protective ef fec t against cardiovascular and 
peripheral vascular diseases in postmenopausal women, 
although the exact mechanisms still await fur ther elucidation. 
It is generally believe that one of the mechanisms of this 
cardioprotective ef fec t is a direct action of oestrogen on vessels 
leading to an improvement of blood flow. 
Due to technical diff icul t ies in direct measurement of 
vascular blood flow, a variety of indirect methods have been 
used and the most popular one was Doppler ultrasound study. 
Previous observational studies have documented a beneficial 
effect of HRT on central arteries in postmenopausal women, 
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re f lec ted by ei ther a drop in the pulsat i l i ty index (PI) or a rise 
in the peak flow veloci ty by Doppler u l t rasound examinat ions . 
The changes of these 2 Doppler parameters have been 
interpreted to represent an improvement of blood f low in these 
women (Gangar et al, 1991; Penott i et al，1993; Pines et al, 
1991). Never theless , most of these studies lacked controls , and 
operators were not bl inded to the t reatment which might have 
lead to measurement bias. 
VI.A.1. The Pilot Study 
The feasibi l i ty of the current study was conf i rmed by our 
pilot study, which shows that 2 of the 4 peripheral arteries 
assessed demonstrate a s ignif icant reduct ion in vascular 
resis tance af ter 2 months of treatment of HRT. According to 
this pilot study, a sample size of 16 is adequate to derive a 
desirable result . The pilot study enables the investigator to be 
famil iar with the techniques of the Doppler ultrasound 
measurement and to recognize the optimal control of the 
environment when assessing the peripheral vascular resistance 
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of the objec ts . However the pilot s tudy is a small 
unrandomized , observat ional study which lacks control and 
bl inding. Therefore a randomized control s tudy is required to 
exclude any poss ible bias on systemic errors. 
VLA.2. The Originality of the Research 
This study was the f i rs t randomized study designed 
speci f ica l ly to investigate the e f fec t of HRT on peripheral 
vascular flow. In order to study the long term ef fec t of HRT, 
each pat ient was studies for 6 months, which is a relat ively 
long fo l low up study compared with previous studies. 
This study was also the f i rs t one to investigate the 
resis tance of peripheral blood flow with oral route of HRT as 
most previous studies had concentrated on the ef fec ts of 
parenteral oestrogen on blood flow (Penotti et al, 1993; Gangar 
et al，1991). 
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This is also the f i rs t study to investigate the relat ionship 
between serum oestradiol level and peripheral vascular blood 
flow. 
VI.B. Study Population 
In our study, only patients with bilateral salpingo-
oophorectomy were recruited. This consti tute a more 
homogenous group of pat ients in whom the timing of 
menopause was well defined. The recruitment of patients with 
natural menopause was also considered to be ethically 
unacceptable because these patients might have been 
randomized to receive oestrogen only HRT, which has been 
proven to increase the risk of endometrial hyperplasia and 
carcinoma. Moreover, a significant number of patients with 
natural menopause when prescribed combined continuous 
oestrogen and progestogen HRT will have vaginal bleeding, 
which is the commonest cause for discontinuation of treatment, 
and therefore a higher drop out rate of the study will be 
140 
expected. Therefore , only pat ients with surgical menopause 
were recrui ted. There is no evidence to suggest that there is 
any quali tat ive d i f ference in physiological or pathological 
changes associated with natural or surgical menopause. It is 
therefore believed that the f indings of this study should be 
applicable to both surgical and natural menopause. 
Medical diseases such as diabetes mell i tus and 
hypertension are common among postmenopausal women. 
These medical condit ions themselves may cause vascular 
diseases. To avoid any confounding effect , patients with 
signif icant medical diseases were therefore excluded in this 
study. 
141 
VI.C. Doppler ultrasound as a measurement of 
vascular resistance and blood flow 
Due to technica l d i f f i cu l t i e s in direct measurement of 
vascular b lood f low, indirect methods were used in the major i ty 
of s tudies in this area of research, such as p le thysmography, 
occulople thysmography, duplex imaging and Doppler 
u l t rasound blood flow detect ion which is the commonest use 
modal i ty . 
It is possible to calculate vascular flow, which is def ined 
as the volume of blood passed through in a given time period, 
f rom Doppler ul t rasound measurements including the cross-
sect ional area of vessel of interest and t ime-related blood f low 
velocity. However, this way of est imation is very inaccurate 
because the velocity of blood f low is not constant within a 
cross-sect ion of a vessel，that is the closer to the vessel wall, 
the lower the velocity. Therefore , this Doppler parameter is 
seldom used in clinical research. 
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On the other hand, pulsa t i l i ty index (PI) has been widely 
accepted as a re l iable Doppler index in represent ing vascular 
res is tance . It has been used extensively in predic t ing disease in 
obstetr ic prac t ice (Vyas et al，1989; Vyas et al, 1990). The 
pulsa t i l i ty index was thought to represent flow res is tance distal 
to the sampling point , thus providing an index of distal arterial 
tone (Thaler et al，1990). The lower the PI, the lower the 
vascular res is tance . Under certain l imitat ions, in par t icular 
with a constant per fus ion pressure , blood flow is inversely 
re la ted to vascular res is tance and therefore PI. The 
measurement of PI is independent of the angle of the ul t rasound 
beam，unlike the Doppler measurement of peak flow velocity. 
Therefore , PI has been chosen as the method in our study to 
assess vascular changes associated with HRT. 
VI.C.1. Reliability of Doppler study 
In order to obtained an accurate measurement of PI, 
potential confounders (such as noise，ambient temperature and 
food intake) were controlled for during each assessment. All 
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ultrasound examinat ions were performed by one single 
operator. The reproducibi l i ty of the measurements was tested 
before the commencement of the study and the intra-observer 
error have been found to be 4 .6% only. 
During each assessment, all physical environmental 
variables including room temperature, noise and light were kept 
constant. The examination started only when the blood 
pressure and heart rate remained stable, which reduced the 
ef fec t on PL Besides, pat ients were instructed to wore similar 
clothing and had similar food intake during each visit. 
Therefore, these effects on PI could be kept to minimum. At 
each fol low-up, the patient were inquired about any significant 
change in l ife-style or commencement of any new medication, 
which might have effect on the Doppler examination. 
Although effor ts had been made to minimize effects of 
these confounding factors, I have to admit that it was 
impossible to eliminate them all. Some of these factors are 
diff icul t to controlled for, for instance, food intake of patients 
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could not be exact ly the same every time. The psychological 
factor of the pat ients is par t icular ly d i f f icul t to control for . 
However, the inf luence of these confounding fac tors are fur ther 
reduced by randomizat ion of study subjects and the 
introduct ion of a control group. 
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VI.D. Pulsatility Index and Hormone Replacement 
Therapy 
The resul t of PI study suggested that the vascular 
res is tance were s ignif icant ly lower, and therefore blood flow 
were increased af te r HRT. 
At 2-month assessment , there was a t rend that the PI 
values in all vessels in the t reatment groups were lesser than 
those of the pre- t reatment assessment, and this d i f fe rence was 
stat is t ical ly s ignif icant in at least two vessels in each of the 2 
t reatment groups receiving HRT (Table V.3). Among those 
receiving oestrogen alone，the PI values in three out of four 
vessels were reduced s ignif icant ly except the radial artery, 
while among those with combined therapy two vessels had a 
s ignif icant ly reduced PI value (p<0.05). On the other hand, 
there was no significant change in PI in any of the 4 arteries 
studied in the control group (p > 0.05). 
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The resul t s were in agreement with the hypo thes i s that 
oes t rogen rep lacement acted direct ly on the vessel wall , causing 
vasodi la ta t ion . This f ind ing was in accordance to previous 
s tudies (Bourne et al, 1990; Penot t i et al, 1993; Gangar et al， 
1991). They all found that HRT have an acute e f f ec t of 
vascular blood flow on central arteries. 
At 4 and 6 months of fo l low-up, similar t rend of changes 
were demonst ra ted and at least one vessel in each t reatment 
groups had s ignif icant reduct ion in PI value. This suggested 
that the improvement in blood f low was not only an acute e f fec t 
a f te r oestrogen therapy. Again，there was no s ignif icant change 
in any the vessels in the control group. 
However , it appears there was a trend that PI was slightly 
increase af ter 4 and 6 months compared to the PI at 2 months, 
al though PI in 6 months was still lower than that before 
t reatment . This f inding was contrary to that of Gangar and 
associates (1991)，who studied each subject for 22 weeks and 
concluded that the longer the duration of t reatment with 
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oestradiol, the greater the decrease in PI (p < 0.05). Our result 
did not support this continuous decline in PI af ter 2 month of 
treatment. Numerous in vitro and in vivo studies have 
demonstrated that hormones usually exert their ef fec t via 
specific receptors. Both oestrogen and progestin receptors have 
been identif ied in human vascular trees (e.g. coronary vessels 
and peripheral arteries). The vascular ef fec t of HRT is 
probably mediated by this hormone-receptor mechanism. The 
current dosage of HRT may have already saturated these 
receptors on vessels and therefore further reduction in PI was 
not observed after more than 2 months of treatment. On the 
other hand，it is impossible to drawn any firm conclusion from 
our findings whether there is a reduction in the vascular effect 
of HRT after more than 2 months of treatment because of the 
limited sample size. If this reduction of effect is genuine, this 
could be due to drug intolerance. Further study is required to 
examine the difference in short term and long term vascular 
effects of HRT. 
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The resul t s of this s tudy were compat ib le with that of 
previous s tudies pe r fo rmed in large arter ies , that is oes t rogen 
reduces vascular res is tance and poss ib ly increases blood flow. 
Sarrel et al (1989，1990) and de Ziegler et al (1991) have 
demonst ra ted that oestrogen improves vascular flow while other 
s tudies have conf i rmed the improvement in ar ter ial pulsa t i l i ty 
in the presence of oestrogen. The mechanism fo r this arterial 
vasodi la ta t ion and improved pulsat i l i ty index is most l ikely 
media tes by act ivat ion of pros tacycl in synthetase activi ty. This 
leads to vasodi la ta t ion, improved blood flow, reduced risk of 
thrombosis and reduced risk of damage due to a therosclerosis 
(Sarrel et al, 1989 & 1990; Wren et al, 1989; Brenner et al, 
1989; Vane et al，1990). 
The action of oestrogen in producing vasodilatat ion, 
improved blood flow is almost certainly mediated through a 
classical hormone - receptor interact ion within cells of the 
artery wall and within platelets circulat ing in blood. 
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In Group 3 there were s igni f icant reduc t ions in PI in at 
least 1 vessel a f t e r 2 months and these pers is ted a f te r 6 months . 
This f ind ing shows that combined oes t rogen-proges togen 
t rea tment can reduce per iphera l vascular res is tance . Though 
the number of ar ter ies having s igni f icant reduct ion in vascular 
res is tance in Group 3 was less than that in Group 2. Because 
of the d i f f i cu l t i e s involved in conduct ing this s tudy and the 
small sample size，we can not conclude that adding progestogen 
a t tenuates the e f fec t of oestrogen on per ipheral vascular 
system. To prove this we need fur ther invest igat ion, perhaps 
by increas ing the sample size. 
VI.E. Effects of Oestrogen on Pulsatility Index 
We have chosen 360 pmol/1 as the cutoff for the analysis 
of the associat ion between serum oestradiol and PI because this 
is the reference value of oestrogen level in our laboratory 
below which the level will be considered to be compatible with 
menopause. In pat ients with serum oestradiol level less than 
360 pmol/1 the PI indices of all arteries measured were 
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s ignif icant ly higher than those in pat ients with serum oestradiol 
level equal or greater than 360 pmol/1 (Table V.6.) . 
Although it would be more informative to perform a 
regression analysis between serum oestradiol level and PI, this 
was not done because a s ignif icant proport ion of samples had 
serum oestradiol level below 90 pmol/1. Below this level, the 
exact serum oestradiol level were not given. 
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VI.F. Conclusion 
The resul ts of this study have demonstrated that oestrogen 
replacement therapy is associated with a s ignif icant reduction 
in peripheral vascular resis tance and possibly increase in 
vascular blood flow. Moreover we can conclude that combined 
oestrogen-progestogen replacement is also associated with a 
signif icant reduction in peripheral vascular resistance. This 
study has also shown that PI is negatively correlated with 
serum oestradiol concentration. The vascular ef fec t of 
oestrogen is not only acute and persists to the end of the study 
(6 months). 
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VI.G. Future Directions 
The introduction of HRT has opened a huge area for 
research. There is good evidence to support that the use of 
HRT is associated with a benefic ia l changes in the vasculature. 
Further research should be directed to the underlying 
mechanisms through which oestrogen leads to vasodilatat ion. 
There is evidence to suggest that oestrogens have anti-oxidant 
propert ies (Niki et al, 1990)，which may play an important role 
in the vascular protective effect of oestrogen. Other 
noninvasive tests, such as those described by Celermajer et al 
(1992) in the detection of endothelial dysfunct ion, should be 
evaluated and may be more appropriate then Doppler ultrasound 
in fur ther research in this area. 
Although there is little doubt that oestrogen-induced 
vascular changes is not only an acute event but will last for at 
least 6 months, it is still unclear how long after commencement 
of HRT will the maximum effects be achieved. It is also 
unclear how quickly will this vascular changes disappear if 
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HRT is discontinued. Further studies with much larger sample 
size, or with a more sensitive study method, is required. 
At present , most women received a standard dose of HRT. 
It is unlikely that the optimal dose of HRT is the same for all 
patients. It is also likely that the optimal dose would be 
di f ferent for the alleviation of postmenopausal symptoms, for 
the prevention of osteoporosis and for the cardioprotective 
effects . More information is required to enable a more 
individualized HRT treatment plan so that the side ef fec ts could 
be minimized with maximal therapeutic effects . 
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